

History of Erythropoiesis-Stimulating Agents, the Development and Future of Anemia Treatment in Nephrology

American Journal of Nephrology

45, 235-247

DOI: 10.1159/000455387

Citation Report

#	ARTICLE	IF	CITATIONS
1	Colony-stimulating factor (CSF) radioimmunoassay: detection of a CSF subclass stimulating macrophage production.. Proceedings of the National Academy of Sciences of the United States of America, 1979, 76, 2969-2973.	3.3	157
2	Cellular regulation of hemoglobin switching: evidence for inverse relationship between fetal hemoglobin synthesis and degree of maturity of human erythroid cells.. Proceedings of the National Academy of Sciences of the United States of America, 1979, 76, 6420-6424.	3.3	114
3	Granulocyte/macrophage-, megakaryocyte-, eosinophil- and erythroid-colony-stimulating factors produced by mouse spleen cells. Biochemical Journal, 1980, 185, 301-314.	1.7	132
5	Specific interaction of murine colony-stimulating factor with mononuclear phagocytic cells.. Journal of Cell Biology, 1980, 85, 153-159.	2.3	258
6	Synthesis and release of erythroid colony- and burst-potentiating activities by purified populations of murine peritoneal macrophages. Journal of Experimental Medicine, 1980, 151, 839-852.	4.2	66
7	The biological properties of endotoxin-free human erythropoietin. Biochemical Journal, 1981, 198, 17-21.	1.7	8
8	Tumor-promoting phorbol esters stimulate myelopoiesis and suppress erythropoiesis in cultures of mouse bone marrow cells.. Proceedings of the National Academy of Sciences of the United States of America, 1981, 78, 4402-4406.	3.3	33
10	Characterization of a monoclonal antibody to human erythropoietin.. Proceedings of the National Academy of Sciences of the United States of America, 1982, 79, 5465-5469.	3.3	26
11	Specific differentiation events induced by erythropoietin in cells infected in vitro with the anemia strain of Friend virus.. Proceedings of the National Academy of Sciences of the United States of America, 1982, 79, 635-639.	3.3	41
12	Erythropoietin causes down regulation of colony-stimulating factor (CSF-1) receptors on peritoneal exudate macrophages of the mouse.. Journal of Cell Biology, 1983, 97, 1945-1949.	2.3	13
13	Site-specific antibodies to human erythropoietin directed toward the NH2-terminal region.. Proceedings of the National Academy of Sciences of the United States of America, 1983, 80, 3651-3655.	3.3	44
14	Mouse yolk sac and intraembryonic tissues produce factors able to elicit differentiation of erythroid burst-forming units and colony-forming units, respectively.. Proceedings of the National Academy of Sciences of the United States of America, 1984, 81, 1453-1456.	3.3	33
15	Cloning and expression of human erythropoietin cDNA in Escherichia coli.. Proceedings of the National Academy of Sciences of the United States of America, 1984, 81, 2708-2712.	3.3	71
16	Specific binding of erythropoietin to spleen cells infected with the anemia strain of Friend virus.. Proceedings of the National Academy of Sciences of the United States of America, 1984, 81, 7574-7578.	3.3	117
17	Cloning and expression of the human erythropoietin gene.. Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 7580-7584.	3.3	1,026
18	Purification and partial amino acid sequence of asialo murine granulocyte-macrophage colony stimulating factor.. Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 292-296.	3.3	69
19	Colony formation by primitive hemopoietic progenitor cells in serum-free medium.. Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 775-779.	3.3	39
20	Specific binding of radioiodinated granulocyte-macrophage colony-stimulating factor to hemopoietic cells.. EMBO Journal, 1985, 4, 933-939.	3.5	132

#	ARTICLE	IF	CITATIONS
21	Human embryonic hemopoiesis. Kinetics of progenitors and precursors underlying the yolk sac—liver transition.. <i>Journal of Clinical Investigation</i> , 1986, 78, 51-60.	3.9	265
22	Chromosomal assignment of the human erythropoietin gene and its DNA polymorphism.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1986, 83, 6920-6924.	3.3	113
23	Human erythropoietin gene: high level expression in stably transfected mammalian cells and chromosome localization.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1986, 83, 6465-6469.	3.3	143
24	Continuous production of erythropoietin by an established human renal carcinoma cell line: development of the cell line.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1986, 83, 165-169.	3.3	32
25	Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis.. <i>BMJ: British Medical Journal</i> , 1987, 295, 1017-1020.	2.4	221
26	Amino acid sequence of S-adenosyl-L-homocysteine hydrolase from rat liver as derived from the cDNA sequence.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1987, 84, 719-723.	3.3	62
27	Specific binding of erythropoietin to its receptor on responsive mouse erythroleukemia cells.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1987, 84, 4126-4130.	3.3	103
28	Growth of human hemopoietic colonies in response to recombinant gibbon interleukin 3: comparison with human recombinant granulocyte and granulocyte-macrophage colony-stimulating factor.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1987, 84, 6765-6769.	3.3	96
29	Hematopoietic growth factors.. <i>Journal of Clinical Investigation</i> , 1987, 79, 1549-1557.	3.9	450
30	Erythropoietin in haemangioblastoma: Immunohistochemical and electron microscopy studies. <i>Acta Neurochirurgica</i> , 1987, 85, 56-62.	0.9	8
31	Nutritional management of children with chronic renal failure. <i>Pediatric Nephrology</i> , 1987, 1, 195-211.	0.9	45
32	Extraction of an erythropoietin-like factor from bovine serum albumin (cohn fraction V). <i>In Vitro Cellular & Developmental Biology</i> , 1987, 23, 361-366.	1.0	13
33	Effect of human recombinant erythropoietin on human hemopoietic progenitor cells in vitro. <i>Klinische Wochenschrift</i> , 1988, 66, 236-240.	0.6	13
34	The thermal stability of oligonucleotide duplexes is sequence independent in tetraalkylammonium salt solutions: application to identifying recombinant DNA clones. <i>Nucleic Acids Research</i> , 1988, 16, 4637-4650.	6.5	133
35	Genetic markers on chromosome 7.. <i>Journal of Medical Genetics</i> , 1988, 25, 294-306.	1.5	9
36	Identification of the receptor for erythropoietin on human and murine erythroleukemia cells and modulation by phorbol ester and dimethyl sulfoxide.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1988, 85, 6513-6517.	3.3	98
37	Down-regulation of c-myc gene expression is a prerequisite for erythropoietin-induced erythroid differentiation.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1988, 85, 8900-8904.	3.3	185
38	Erythropoietin: the developing story. <i>BMJ: British Medical Journal</i> , 1988, 296, 805-806.	2.4	9

#	ARTICLE	IF	CITATIONS
39	Hemopoietic stem cells: stochastic differentiation and humoral control of proliferation.. Environmental Health Perspectives, 1989, 80, 199-207.	2.8	25
40	Preclinical and clinical studies with the hematopoietic colony-stimulating factors and related interleukins. Immunologic Research, 1989, 8, 185-201.	1.3	24
41	A dose-dependent effect of recombinant erythropoietin on the reticulocyte population of rats. Blut, 1989, 59, 184-187.	1.2	11
42	Polypeptides controlling hematopoietic cell development and activation. Blut, 1989, 58, 117-128.	1.2	41
43	Treatment of the Anaemia of Chronic Renal Failure with Recombinant Human Erythropoietin. Drugs, 1989, 38, 342-345.	4.9	5
44	Polycythemia in transgenic mice expressing the human erythropoietin gene.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 2301-2305.	3.3	130
45	Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 7819-7822.	3.3	278
46	Erythropoietin: an old friend revisited.. BMJ: British Medical Journal, 1990, 300, 621-622.	2.4	4
47	Activation of erythropoietin receptors by Friend viral gp55 and by erythropoietin and down-modulation by the murine Fv-2r resistance gene.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 9985-9989.	3.3	108
48	Recombinant DNA and Surgery. Annals of Surgery, 1990, 212, 178-186.	2.1	10
49	Role of erythropoietin in adaptation to hypoxia. Experientia, 1990, 46, 1197-1201.	1.2	28
50	Recombinant human erythropoietin therapy in children maintained by haemodialysis. Pediatric Nephrology, 1990, 4, 618-622.	0.9	30
51	Production of recombinant human erythropoietin in Bowes melanoma cells in suspension culture. Applied Microbiology and Biotechnology, 1990, 34, 198-202.	1.7	1
52	A retinoic acid responsive gene MK found in the teratocarcinoma system is expressed in spatially and temporally controlled manner during mouse embryogenesis.. Journal of Cell Biology, 1990, 110, 607-616.	2.3	247
53	Haematology. Postgraduate Medical Journal, 1990, 66, 595-611.	0.9	1
54	The Potential of Biotechnology to Improve the Quality of Life of Patients with Renal Failure. Drug Safety, 1991, 6, 1-7.	1.4	9
55	Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 5680-5684.	3.3	839
56	Clinical Pharmacokinetics of Epoetin (Recombinant Human Erythropoietin). Clinical Pharmacokinetics, 1991, 20, 99-113.	1.6	116

#	ARTICLE	IF	CITATIONS
57	Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 8725-8729.	3.3	226
58	Erythropoiesis and erythropoietin levels in renal transplant recipients. Klinische Wochenschrift, 1991, 69, 53-58.	0.6	28
59	Erythropoietin gene expression in haemopoietic cell lines. Cytotechnology, 1991, 6, 131-136.	0.7	0
60	Sequence and structural relationships in the cytokine family. The Protein Journal, 1992, 11, 321-331.	1.1	15
61	Influence on erythropoietin levels of treatment with cisplatinum-endoxan. Archives of Gynecology and Obstetrics, 1992, 252, 49-53.	0.8	3
62	Recombinant human erythropoietin (rHuEPO): Cross-linking with disuccinimidyl esters and identification of the interfacing domains in EPO. Protein Science, 1993, 2, 1441-1451.	3.1	18
63	Effect of recombinant human erythropoietin after allogeneic bone marrow transplantation. Annals of Hematology, 1993, 67, 169-173.	0.8	15
64	Nephrology, dialysis and transplantation. Postgraduate Medical Journal, 1993, 69, 516-546.	0.9	6
65	Effects of azathioprine on response of renal anaemia to subcutaneous recombinant human erythropoietin.. Journal of Clinical Pathology, 1993, 46, 41-44.	1.0	13
66	The use of haemopoietic growth factors in blood disorders.. Archives of Disease in Childhood, 1994, 71, 543-547.	1.0	4
67	Inadequate erythropoietin response to anemia: definition and clinical relevance. Annals of Hematology, 1994, 68, 215-223.	0.8	71
68	Effect of recombinant human erythropoietin on synthesis of methylguanidine in uraemic patients on haemodialysis or continuous ambulatory peritoneal dialysis. International Urology and Nephrology, 1994, 26, 701-705.	0.6	0
69	The β phosphorylase kinase gene, Phkg, maps to mouse Chromosome 5 near Gus. Mammalian Genome, 1994, 5, 15-18.	1.0	5
70	Role of hydrogen peroxide in hypoxia-induced erythropoietin production. Biochemical Journal, 1994, 303, 507-510.	1.7	232
71	Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 11557-11561.	3.3	116
72	Characterization of a human glycoprotein (erythropoietin) produced in cultured tobacco cells. Plant Molecular Biology, 1995, 27, 1163-1172.	2.0	141
73	The transcription factors ATF-1 and CREB-1 bind constitutively to the hypoxia-inducible factor-1 (HIF-1)DNA recognition site. Nucleic Acids Research, 1995, 23, 4542-4550.	6.5	224
74	Pharmacological Approaches to Reduce Perioperative Transfusion Requirements in the Aged. Drugs and Aging, 1995, 6, 91-104.	1.3	6

#	ARTICLE	IF	CITATIONS
75	A sequential dimerization mechanism for erythropoietin receptor activation.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 9471-9476.	3.3	74
76	Erythrocytes as carriers for recombinant human erythropoietin. Pharmaceutical Research, 1996, 13, 869-874.	1.7	41
77	Anaemia of Prematurity. Pharmacoeconomics, 1997, 12, 438-445.	1.7	11
78	Bovine alpha s1-casein gene sequences direct high level expression of human granulocyte-macrophage colony-stimulating factor in the milk of transgenic mice. Transgenic Research, 1997, 6, 75-84.	1.3	38
79	Large-Scale Sequencing of Two Regions in Human Chromosome 7q22: Analysis of 650 kb of Genomic Sequence around the <i>EPO</i> and <i>CUTL1</i> Loci Reveals 17 Genes. Genome Research, 1998, 8, 1060-1073.	2.4	57
80	Human erythropoietin dimers with markedly enhanced in vivo activity. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 1184-1188.	3.3	59
81	Oligosaccharides as immunodeterminants of erythropoietin for two sets of anti-carbohydrate antibodies. The Protein Journal, 2000, 19, 631-635.	1.1	10
82	Development and characterization of novel erythropoiesis stimulating protein (NESP). British Journal of Cancer, 2001, 84, 3-10.	2.9	426
83	Androgen therapy for anemia in elderly uremic patients. International Urology and Nephrology, 2001, 32, 549-557.	0.6	11
84	Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 5181-5186.	3.3	155
85	Past, present and future of erythropoietin use in the elderly. International Urology and Nephrology, 2002, 33, 187-193.	0.6	9
87	A novel protective effect of erythropoietin in the infarcted heart. Journal of Clinical Investigation, 2003, 112, 999-1007.	3.9	476
88	Anaemia and heart failure. Heart, 2004, 90, 977-979.	1.2	14
89	Impact of epoetin alfa on clinical end points in patients with chronic renal failure: A meta-analysis. Kidney International, 2004, 65, 757-767.	2.6	1,202
90	Overexpression of human erythropoietin (EPO) affects plant morphologies: retarded vegetative growth in tobacco and male sterility in tobacco and Arabidopsis. Transgenic Research, 2004, 13, 541-549.	1.3	57
91	Anemia and heart failure. Current Heart Failure Reports, 2004, 1, 176-182.	1.3	30
92	Clinical and Economic Impact of Epoetins in Cancer Care. Pharmacoeconomics, 2004, 22, 1029-1045.	1.7	23
93	A Study of the Response of Elderly Patients with End-Stage Renal Disease to Epoetin Alfa or Beta. Drugs and Aging, 2004, 21, 187-201.	1.3	8

#	ARTICLE	IF	CITATIONS
94	Treatment of anemia in the patient with heart failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2005, 7, 327-332.	0.4	4
95	Interaction of Polysorbate 80 with Erythropoietin: A Case Study in Protein-Surfactant Interactions. <i>Pharmaceutical Research</i> , 2005, 22, 1186-1194.	1.7	49
96	Current Methods for Detecting Antibodies against Erythropoietin and Other Recombinant Proteins. <i>Vaccine Journal</i> , 2005, 12, 28-39.	3.2	42
97	The effects of nocturnal hemodialysis compared to conventional hemodialysis on change in left ventricular mass: Rationale and study design of a randomized controlled pilot study. <i>BMC Nephrology</i> , 2006, 7, 2.	0.8	21
98	Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects. <i>Kidney International</i> , 2006, 69, 679-684.	2.6	34
99	Effects of protein aggregates: An immunologic perspective. <i>AAPS Journal</i> , 2006, 8, E501-E507.	2.2	1,162
100	Dynamic Control of Oligosaccharide Modification in the Mammary Gland: Linking Recombinant Human Erythropoietin. <i>Transgenic Research</i> , 2006, 15, 37-55.	1.3	7
101	The epidemics of cardiovascular disease in elderly patients with chronic kidney disease – Two facets of the same problem. <i>International Urology and Nephrology</i> , 2006, 38, 371-379.	0.6	13
102	Anemia, chronic renal disease and congestive heart failure – the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists. <i>International Urology and Nephrology</i> , 2006, 38, 295-310.	0.6	106
104	Anemia and cardiovascular disease in diabetic nephropathy. <i>Current Diabetes Reports</i> , 2006, 6, 213-218.	1.7	26
105	Anemia and diabetic nephropathy. <i>Current Diabetes Reports</i> , 2006, 6, 469-472.	1.7	12
106	Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 5965-5970.	3.3	129
107	Progress Toward A Nonviral Gene Therapy Protocol for The Treatment of Anemia. <i>Human Gene Therapy</i> , 2007, 18, 269-285.	1.4	52
108	Feasibility of a Multiplex Flow Cytometric Bead Immunoassay for Detection of Anti-Epoetin Alfa Antibodies. <i>Vaccine Journal</i> , 2007, 14, 1165-1172.	3.2	13
109	Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials. <i>Cmaj</i> , 2007, 177, 725-734.	0.9	106
110	Too much of a good thing. <i>BMJ: British Medical Journal</i> , 2007, 334, 978-980.	2.4	5
111	An integrated approach to prognosis using protein microarrays and nonparametric methods. <i>Molecular Systems Biology</i> , 2007, 3, 123.	3.2	22
112	Vitamin D in patients with renal failure: A summary of observational mortality studies and steps moving forward. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2007, 103, 487-490.	1.2	38

#	ARTICLE	IF	CITATIONS
113	Chronic Kidney Disease Mineral Bone Disorder and Health-Related Quality of Life Among Incident End-Stage Renal-Disease Patients. , 2007, 17, 305-313.		20
114	Drug-Induced Cardiovascular Disorders. Drug Safety, 2007, 30, 783-804.	1.4	32
115	Guidelines and Recommendations for the Management of Anaemia in Patients with Lymphoid Malignancies. Drugs, 2007, 67, 175-194.	4.9	8
116	Stimulating erythropoiesis in inflammatory bowel disease associated anemia. World Journal of Gastroenterology, 2007, 13, 4798.	1.4	35
118	Relation between level or change of hemoglobin and generic and disease-specific quality of life measures in hemodialysis. Quality of Life Research, 2007, 16, 755-765.	1.5	16
119	Therapeutic potential of erythropoietin in cardiovascular disease: Erythropoiesis and beyond. Current Heart Failure Reports, 2007, 4, 127-133.	1.3	9
120	Acute myositis in a patient with systemic sclerosis after the administration of darbepoetin alpha. Rheumatology International, 2008, 28, 293-294.	1.5	1
121	Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care. Medical Oncology, 2008, 25, 22-29.	1.2	11
122	Anemia in children with chronic kidney disease. Pediatric Nephrology, 2008, 23, 209-219.	0.9	74
123	Erythropoietic Agents and the Elderly. Seminars in Hematology, 2008, 45, 267-275.	1.8	15
124	Evaluation and Determinants of Underprescription of Erythropoiesis Stimulating Agents in Pre-Dialysis Patients with Anaemia. Nephron Clinical Practice, 2008, 108, c67-c74.	2.3	8
125	White Thrombus Formation in Blood Tubing Lines in a Chronic Hemodialysis Unit. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 382-386.	2.2	7
126	Optimal predialysis care. CKJ: Clinical Kidney Journal, 2008, 1, iv7-iv13.	1.4	5
127	Antibody-mediated pure red cell aplasia (PRCA) on switching from darbepoetin alfa to epoetin beta: what are the implications?. CKJ: Clinical Kidney Journal, 2008, 1, 230-232.	1.4	1
128	Left ventricular dysfunction in the haemodialysis population. CKJ: Clinical Kidney Journal, 2008, 1, 199-205.	1.4	21
129	Hemoglobin Targets and Blood Transfusions in Hemodialysis Patients without Symptomatic Cardiac Disease Receiving Erythropoietin Therapy. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1669-1675.	2.2	33
130	Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease Patient. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 505-521.	2.2	472
131	Effects of Graded Doses of Testosterone on Erythropoiesis in Healthy Young and Older Men. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 914-919.	1.8	310

#	ARTICLE	IF	CITATIONS
132	Health-Related Quality of Life and Hemoglobin Levels in Chronic Kidney Disease Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 33-38.	2.2	131
133	The future of European Nephrology 'Guidelines'--a declaration of intent by European Renal Best Practice (ERBP). <i>CKJ: Clinical Kidney Journal</i> , 2009, 2, 213-221.	1.4	7
134	Anemia, Diabetes, and Chronic Kidney Disease. <i>Diabetes Care</i> , 2009, 32, 1320-1326.	4.3	158
135	The Effect of Iron and Erythropoietin Treatment on the A1C of Patients With Diabetes and Chronic Kidney Disease. <i>Diabetes Care</i> , 2010, 33, 2310-2313.	4.3	93
136	Individualizing anaemia therapy. <i>CKJ: Clinical Kidney Journal</i> , 2010, 3, 519-526.	1.4	0
137	Timing of Erythropoiesis-Stimulating Agent Initiation and Adverse Outcomes in Nondialysis CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 882-888.	2.2	19
138	Beyond efficacy and safety--the need for convenient and cost-effective iron therapy in health care. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, i14-i19.	1.4	6
139	Introducing iron isomaltoside 1000 (Monofer(R))--development rationale and clinical experience. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, i10-i13.	1.4	6
140	The future of intravenous iron in nephrology. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, i6-i9.	1.4	0
141	Iron treatment and the TREAT trial. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, i3-i5.	1.4	4
142	Erythropoietin: New Directions for the Nervous System. <i>International Journal of Molecular Sciences</i> , 2012, 13, 11102-11129.	1.8	78
143	Management of adverse events during the treatment of chronic hepatitis C infection. <i>Clinical Liver Disease</i> , 2012, 1, 54-57.	1.0	5
144	Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. <i>Blood</i> , 2013, 122, 2943-2964.	0.6	567
145	Chapter 5: Referral to specialists and models of care. <i>Kidney International Supplements</i> , 2013, 3, 112-119.	4.6	38
146	Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD. <i>Kidney International Supplements</i> , 2013, 3, 91-111.	4.6	38
147	Chapter 3: Management of progression and complications of CKD. <i>Kidney International Supplements</i> , 2013, 3, 73-90.	4.6	121
148	Alternatives to blood transfusion. <i>Lancet, The</i> , 2013, 381, 1855-1865.	6.3	230
149	Pure red cell aplasia after treatment of renal anaemia with epoetin theta. <i>CKJ: Clinical Kidney Journal</i> , 2013, 6, 539-542.	1.4	10

#	ARTICLE	IF	CITATIONS
150	Signaling hypoxia by hypoxia-inducible factor protein hydroxylases: a historical overview and future perspectives. <i>Hypoxia (Auckland, N Z)</i> , 2014, 2, 197.	1.9	40
151	Mineral Metabolism Markers Are Associated with Myocardial Infarction and Hemorrhagic Stroke but Not Ischemic Stroke in Hemodialysis Patients: A Longitudinal Study. <i>PLoS ONE</i> , 2014, 9, e114678.	1.1	17
152	Major Declines in Epoetin Dosing after Prospective Payment System Based on Dialysis Facility Organizational Status. <i>American Journal of Nephrology</i> , 2014, 40, 554-560.	1.4	13
153	Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs. <i>World Journal of Nephrology</i> , 2014, 3, 156.	0.8	79
154	Effect of occasional epoetin use in combination with a stable darbepoetin dosage on anemia management in hemodialysis patients. <i>ClinicoEconomics and Outcomes Research</i> , 2014, 6, 531.	0.7	2
155	Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. <i>The Cochrane Library</i> , 2014, , CD010590.	1.5	75
156	Potential Impact of Subsequent Entry Biologics in Nephrology Practice in Canada. <i>Canadian Journal of Kidney Health and Disease</i> , 2014, 1, 32.	0.6	3
157	A Budget Impact Analysis of the Introduction of Erythropoiesis Stimulating Agent Subsequent Entry Biologics for the Treatment of Anemia of Chronic Kidney Disease in Canada. <i>Canadian Journal of Kidney Health and Disease</i> , 2014, 1, 28.	0.6	4
158	Erythropoietin and Cancer: The Unintended Consequences of Anemia Correction. <i>Frontiers in Immunology</i> , 2014, 5, 563.	2.2	75
159	Erythropoietin Combined with Liposomal Amphotericin B Improves Outcome during Disseminated Aspergillosis in Mice. <i>Frontiers in Immunology</i> , 2014, 5, 502.	2.2	5
160	Endothelial Nitric Oxide Synthase Mediates the Cerebrovascular Effects of Erythropoietin in Traumatic Brain Injury. <i>Frontiers in Immunology</i> , 2014, 5, 494.	2.2	15
161	A randomized crossover study of single biweekly administration of epoetin- α compared with darbepoetin- α in chronic kidney disease patients not receiving dialysis. <i>Kidney Research and Clinical Practice</i> , 2014, 33, 210-216.	0.9	2
162	Regulatory and clinical considerations for biosimilar oncology drugs. <i>Lancet Oncology, The</i> , 2014, 15, e594-e605.	5.1	99
163	Formulary Selection Criteria for Biosimilars: Considerations for US Health-System Pharmacists. <i>Hospital Pharmacy</i> , 2014, 49, 813-825.	0.4	33
164	A randomized control trial to assess the impact of vitamin D supplementation compared to placebo on vascular stiffness in chronic kidney disease patients. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 156.	0.7	7
165	Efficacy and Safety Data of Subsequent Entry Biologics Pertinent to Nephrology Practice: A Systematic Review. <i>Canadian Journal of Kidney Health and Disease</i> , 2014, 1, 34.	0.6	4
166	Chronic kidney disease in the elderly: evaluation and management. <i>Clinical Practice (London, England)</i> , 2014, 11, 525-535.	0.1	161
167	Guidelines on the treatment of anemia of chronic renal failure using recombinant human erythropoietin: AssociaÃ§Ã£o Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: AssociaÃ§Ã£o MÃ©dica Brasileira â€œ 2014. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2014, 36, 450-453.	0.7	0

#	ARTICLE	IF	CITATIONS
168	Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. <i>BMJ Open Diabetes Research and Care</i> , 2014, 2, e000011.	1.2	31
169	Erythropoietin and organ protection: lessons from negative clinical trials. <i>Critical Care</i> , 2014, 18, 526.	2.5	17
170	Clinical Profile and Response to Treatment with Pegylated Interferon α 2b and Ribavirin in Chronic Hepatitis C: A Reappraisal from a Tertiary Care Center in Northern India. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, 101-105.	0.4	5
171	Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. <i>European Journal of Heart Failure</i> , 2015, 17, 1201-1207.	2.9	35
172	Protective effect of erythropoietin against myocardial injury in rats with sepsis and its underlying mechanisms. <i>Molecular Medicine Reports</i> , 2015, 11, 3317-3329.	1.1	30
173	Factors Contributing to Erythropoietin Hyporesponsiveness in Patients on Long-Term Continuous Ambulatory Peritoneal Dialysis: A Cross-Sectional Study. <i>Nephron Extra</i> , 2015, 5, 79-86.	1.1	6
174	Target Hemoglobin May Be Achieved with Intravenous Iron Alone in Anemic Patients with Cardiorenal Syndrome: An Observational Study. <i>CardioRenal Medicine</i> , 2015, 5, 246-253.	0.7	8
175	A combined pre-clinical meta-analysis and randomized confirmatory trial approach to improve data validity for therapeutic target validation. <i>Scientific Reports</i> , 2015, 5, 13428.	1.6	30
176	Predictors of anemia in a multi-ethnic chronic kidney disease population: a case-control study. <i>SpringerPlus</i> , 2015, 4, 233.	1.2	12
177	Early versus delayed erythropoietin for the anaemia of end-stage kidney disease. <i>The Cochrane Library</i> , 2017, 2017, CD011122.	1.5	8
178	Red cell physiology and signaling relevant to the critical care setting. <i>Current Opinion in Pediatrics</i> , 2015, 27, 267-276.	1.0	9
179	Effect of Medicare Dialysis Payment Reform on Use of Erythropoiesis Stimulating Agents. <i>Health Services Research</i> , 2015, 50, 790-808.	1.0	18
180	Nonspecific shielding of unfavorable electrostatic intramolecular interactions in the erythropoietin native state increase conformational stability and limit non-native aggregation. <i>Protein Science</i> , 2015, 24, 803-811.	3.1	3
181	Successful creation of an anemia management algorithm for hemodialysis patients. <i>International Journal of Nephrology and Renovascular Disease</i> , 2015, 8, 65.	0.8	5
182	Anti-Erythropoietin Antibody Associated Pure Red Cell Aplasia Resolved after Liver Transplantation. <i>Case Reports in Transplantation</i> , 2015, 2015, 1-5.	0.1	2
183	What's New in Traumatic Brain Injury: Update on Tracking, Monitoring and Treatment. <i>International Journal of Molecular Sciences</i> , 2015, 16, 11903-11965.	1.8	64
184	Erythropoietin in the General Population: Reference Ranges and Clinical, Biochemical and Genetic Correlates. <i>PLoS ONE</i> , 2015, 10, e0125215.	1.1	38
185	Switching Patients with Non-Dialysis Chronic Kidney Disease from Oral Iron to Intravenous Ferric Carboxymaltose: Effects on Erythropoiesis-Stimulating Agent Requirements, Costs, Hemoglobin and Iron Status. <i>PLoS ONE</i> , 2015, 10, e0125528.	1.1	17

#	ARTICLE	IF	CITATIONS
186	Efficiency of Original versus Generic Intravenous Iron Formulations in Patients on Haemodialysis. PLoS ONE, 2015, 10, e0135967.	1.1	26
187	Impact of Hydroxychloroquine on Atherosclerosis and Vascular Stiffness in the Presence of Chronic Kidney Disease. PLoS ONE, 2015, 10, e0139226.	1.1	23
188	Renal erythropoietin-producing cells in health and disease. Frontiers in Physiology, 2015, 6, 167.	1.3	96
189	High Dose ESAs Are Associated with High iPTH Levels in Hemodialysis Patients with End-Stage Kidney Disease: A Retrospective Analysis. Frontiers in Public Health, 2015, 3, 258.	1.3	9
190	Berberine in Combination with Insulin Has Additive Effects on Titanium Implants Osseointegration in Diabetes Mellitus Rats. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-8.	0.5	13
191	Mechanisms Linking Red Blood Cell Disorders and Cardiovascular Diseases. BioMed Research International, 2015, 2015, 1-12.	0.9	101
192	The Role of Aggregates of Therapeutic Protein Products in Immunogenicity: An Evaluation by Mathematical Modeling. Journal of Immunology Research, 2015, 2015, 1-14.	0.9	18
193	Early Implementation of QbD in Biopharmaceutical Development: A Practical Example. BioMed Research International, 2015, 2015, 1-19.	0.9	47
194	Diverse of Erythropoiesis Responding to Hypoxia and Low Environmental Temperature in Vertebrates. BioMed Research International, 2015, 2015, 1-9.	0.9	11
195	Outcomes Associated with Conventional Accelerated Versus Once-Weekly IV Iron Therapy in Outpatients Undergoing Hemodialysis. Canadian Journal of Hospital Pharmacy, 2015, 68, .	0.1	0
196	The Labile Side of Iron Supplementation in CKD. Journal of the American Society of Nephrology: JASN, 2015, 26, 2612-2619.	3.0	41
197	Anaemia in kidney disease: harnessing hypoxia responses for therapy. Nature Reviews Nephrology, 2015, 11, 394-410.	4.1	235
198	Translational nephrology: what translational research is and a bird's-eye view on translational research in nephrology. CKJ: Clinical Kidney Journal, 2015, 8, 14-22.	1.4	18
199	Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. Annals of Internal Medicine, 2015, 163, 127-134.	2.0	162
200	Role of Vascular Function in Predicting Arteriovenous Fistula Outcomes: An Observational Pilot Study. Canadian Journal of Kidney Health and Disease, 2015, 2, 55.	0.6	11
201	Cause of Death in Patients With Diabetic CKD Enrolled in theÂTrial to Reduce Cardiovascular Events With Aranesp TherapyÂ(TREAT). American Journal of Kidney Diseases, 2015, 66, 429-440.	2.1	29
202	Drug therapies to delay the progression of chronic kidney disease. Clinical Medicine, 2015, 15, 550-557.	0.8	10
203	The evolving role of biosimilars in haematology&“oncology: a practical perspective. Therapeutic Advances in Hematology, 2015, 6, 267-281.	1.1	15

#	ARTICLE	IF	CITATIONS
204	Molecular mechanisms of ischemic preconditioning in the kidney. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, F821-F834.	1.3	67
205	Con: Phosphate binders in chronic kidney diseaseOpponent's comments. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, gfv406.	0.4	6
206	The Diversity of Biosimilar Design and Development: Implications for Policies and Stakeholders. <i>BioDrugs</i> , 2015, 29, 365-372.	2.2	24
207	In Vitro Evaluation of the Link Between Cell Activation State and Its Rheological Impact on the Microscale Flow of Neutrophil Suspensions. <i>Journal of Biomechanical Engineering</i> , 2015, 137, .	0.6	3
208	Considerations and Challenges in Defining Optimal Iron Utilization in Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1238-1247.	3.0	75
209	Onco-nephrology: an appraisal of the cancer and chronic kidney disease links. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1979-1988.	0.4	31
210	Hepcidin and risk of anemia in CKD: a cross-sectional and longitudinal analysis in the CKiD cohort. <i>Pediatric Nephrology</i> , 2015, 30, 635-643.	0.9	39
211	Clinical Outcomes With Use of Erythropoiesis Stimulating Agents in Patients With the HeartMate II Left Ventricular Assist Device. <i>JACC: Heart Failure</i> , 2015, 3, 146-153.	1.9	25
212	Association of High-Sensitivity Cardiac Troponin T and Natriuretic Peptide With Incident ESRD: The Atherosclerosis Risk in Communities (ARIC) Study. <i>American Journal of Kidney Diseases</i> , 2015, 65, 550-558.	2.1	16
213	Sudden cardiac death in end stage renal disease: unlocking the mystery. <i>Journal of Nephrology</i> , 2015, 28, 133-141.	0.9	5
214	Protecting the confidentiality of interim data: Addressing current challenges. <i>Clinical Trials</i> , 2015, 12, 5-11.	0.7	21
215	Biosimilars advancements: Moving on to the future. <i>Biotechnology Progress</i> , 2015, 31, 1139-1149.	1.3	51
216	Association of Fluid Retention With Anemia and Clinical Outcomes Among Patients With Chronic Kidney Disease. <i>Journal of the American Heart Association</i> , 2015, 4, e001480.	1.6	34
218	From Phosphaturia to Cardiovascular Protection. <i>Circulation</i> , 2015, 132, 7-9.	1.6	2
219	Regulatory considerations in oncologic biosimilar drug development. <i>MAbs</i> , 2015, 7, 653-661.	2.6	25
220	Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2930-2937.	3.0	68
221	Ferric pyrophosphate: good things come to those who wait?. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1942-1944.	0.4	1
222	Alternative matrices for therapeutic drug monitoring of immunosuppressive agents using LC-MS/MS. <i>Bioanalysis</i> , 2015, 7, 1037-1058.	0.6	38

#	ARTICLE	IF	CITATIONS
223	Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2578-2587.	3.0	88
224	Blood disorders typically associated with renal transplantation. <i>Frontiers in Cell and Developmental Biology</i> , 2015, 3, 18.	1.8	45
225	Aggregation risk prediction for antibodies and its application to biotherapeutic development. <i>MABs</i> , 2015, 7, 352-363.	2.6	87
226	Risk-based individualisation of target haemoglobin in haemodialysis patients with renal anaemia in the post-TREAT era: theoretical attitudes versus actual practice patterns (MONITOR-CKD5 study). <i>International Urology and Nephrology</i> , 2015, 47, 837-845.	0.6	3
227	Kidney disease as a determinant of cognitive decline and dementia. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 29.	3.0	48
228	Patient Safety Issues in CKD: Core Curriculum 2015. <i>American Journal of Kidney Diseases</i> , 2015, 66, 159-169.	2.1	21
229	Resistance of dialyzed patients to erythropoietin. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2015, 37, 190-197.	0.7	34
230	Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia. <i>American Journal of Kidney Diseases</i> , 2015, 66, 196-205.	2.1	38
231	Association between strict blood pressure control during chronic kidney disease and lower mortality after onset of end-stage renal disease. <i>Kidney International</i> , 2015, 87, 1055-1060.	2.6	64
232	Optimal hemoglobin level for anemia treatment in a cohort of hemodialysis patients. <i>Kidney Research and Clinical Practice</i> , 2015, 34, 20-27.	0.9	10
233	Is It Too Much of a Good Thing? A New Era in Phosphate Binder Therapy in ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2311-2313.	3.0	6
234	Longitudinal changes in hematocrit in hypertensive chronic kidney disease: results from the African-American Study of Kidney Disease and Hypertension (AASK). <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1329-1335.	0.4	6
235	Thresholds of iron markers for iron deficiency erythropoiesis—finding of the Japanese nationwide dialysis registry. <i>Kidney International Supplements</i> , 2015, 5, 23-32.	4.6	28
236	Association of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United States. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1822-1830.	2.2	33
237	Oral or intravenous iron for anemia correction in chronic kidney disease?. <i>Kidney International</i> , 2015, 88, 673-675.	2.6	14
238	The glycocalyx—linking albuminuria with renal and cardiovascular disease. <i>Nature Reviews Nephrology</i> , 2015, 11, 667-676.	4.1	128
239	Discovery and Characterization of Nonpeptidyl Agonists of the Tissue-Protective Erythropoietin Receptor. <i>Molecular Pharmacology</i> , 2015, 88, 357-367.	1.0	13
240	Risk of Stroke in Patients with ESRD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1585-1592.	2.2	41

#	ARTICLE	IF	CITATIONS
241	State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists. <i>International Urology and Nephrology</i> , 2015, 47, 1529-1539.	0.6	11
242	Pharmacoutilization of epoetins in naïve patients with hematological malignancies in an unselected Italian population under clinical practice setting: a comparative analysis between originator and biosimilars. <i>Biologics: Targets and Therapy</i> , 2016, Volume 10, 157-165.	3.0	7
243	The cost-utility of treating anemia with continuous erythropoietin receptor activator or Epoetin versus routine blood transfusions among chronic hemodialysis patients. <i>International Journal of Nephrology and Renovascular Disease</i> , 2016, 9, 35.	0.8	7
244	THE PANC 3 SCORE PREDICTING SEVERITY OF ACUTE PANCREATITIS. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 2016, 29, 5-8.	0.5	4
245	Biosimilars: potential implications for clinicians. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2016, 9, 135.	0.8	20
246	Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease. <i>Journal of Korean Medical Science</i> , 2016, 31, 55.	1.1	3
247	Association of hemoglobin with ankle-brachial index in general population. <i>Clinics</i> , 2016, 71, 375-380.	0.6	1
248	Current status of biosimilars in the treatment of inflammatory bowel diseases. <i>Intestinal Research</i> , 2016, 14, 15.	1.0	16
249	Regulation of platelet count by erythropoiesis-stimulating agents & iron axis in hemodialysis patients. <i>International Journal of Nephrology and Renovascular Disease</i> , 2016, 9, 73.	0.8	1
250	Role of anuria in the relationship between indoxyl sulfate and anemia in peritoneal dialysis patients. <i>Therapeutics and Clinical Risk Management</i> , 2016, Volume 12, 1797-1803.	0.9	7
251	Effects of erythropoiesis-stimulating agents on heart failure patients with anemia: a meta-analysis. <i>Postepy W Kardiologii Interwencyjnej</i> , 2016, 3, 247-253.	0.1	2
252	Comparison of Hemoglobin Levels Before and After Hemodialysis and Their Effects on Erythropoietin Dosing and Cost. <i>Nephro-Urology Monthly</i> , 2016, 8, e38495.	0.0	5
253	Posttranslational Modifications and the Immunogenicity of Biotherapeutics. <i>Journal of Immunology Research</i> , 2016, 2016, 1-15.	0.9	93
254	Erythropoietin Dose and Mortality in Hemodialysis Patients: Marginal Structural Model to Examine Causality. <i>International Journal of Nephrology</i> , 2016, 2016, 1-8.	0.7	17
255	A Genetic Biomarker of Oxidative Stress, the Paraoxonase-1 Q192R Gene Variant, Associates with Cardiomyopathy in CKD: A Longitudinal Study. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-7.	1.9	17
256	Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications. <i>Journal of Immunology Research</i> , 2016, 2016, 1-18.	0.9	154
257	Patient attitudes and understanding about biosimilars: an international cross-sectional survey. <i>Patient Preference and Adherence</i> , 2016, 10, 937.	0.8	106
258	Anticytokine Autoantibodies: Association with Infection and Immune Dysregulation. <i>Antibodies</i> , 2016, 5, 3.	1.2	20

#	ARTICLE	IF	CITATIONS
259	Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia. <i>International Journal of Molecular Sciences</i> , 2016, 17, 28.	1.8	11
260	The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease. <i>PLoS ONE</i> , 2016, 11, e0157323.	1.1	7
261	Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide. <i>International Journal of Nephrology and Renovascular Disease</i> , 2016, 9, 11.	0.8	25
262	Regeneration in the nervous system with erythropoietin. <i>Frontiers in Bioscience - Landmark</i> , 2016, 21, 561-596.	3.0	48
263	Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis. <i>The Cochrane Library</i> , 2016, 2016, CD003266.	1.5	21
264	Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	24
265	Comparison of originator and biosimilar therapeutic monoclonal antibodies using comprehensive two-dimensional liquid chromatography coupled with time-of-flight mass spectrometry. <i>MABs</i> , 2016, 8, 1224-1234.	2.6	76
266	The greatly misunderstood erythropoietin resistance index and the case for a new responsiveness measure. <i>Hemodialysis International</i> , 2016, 20, 392-398.	0.4	28
267	Arteriovenous Access Failure, Stenosis, and Thrombosis. <i>Canadian Journal of Kidney Health and Disease</i> , 2016, 3, 205435811666912.	0.6	65
268	Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example. <i>RMD Open</i> , 2016, 2, e000154.	1.8	21
269	Effects of the prospective payment system on anemia management in maintenance dialysis patients: implications for cost and site of care. <i>BMC Nephrology</i> , 2016, 17, 53.	0.8	7
270	Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. <i>BMC Nephrology</i> , 2016, 17, 97.	0.8	66
271	Pure red cell aplasia. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 51-56.	0.9	45
272	Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 1567-1575.	1.6	88
273	ESRD Payment Reform: First Do No Harm. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 2924-2926.	3.0	3
274	Iron Therapy Challenges for the Treatment of Nondialysis CKD Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1269-1280.	2.2	17
275	Epoetin beta pegol, but not recombinant erythropoietin, retains its hematopoietic effect in vivo in the presence of the sialic acid-metabolizing enzyme sialidase. <i>International Journal of Hematology</i> , 2016, 104, 182-189.	0.7	3
276	Prediction of the molecular mechanisms and potential therapeutic targets for diabetic nephropathy by bioinformatics methods. <i>International Journal of Molecular Medicine</i> , 2016, 37, 1181-1188.	1.8	14

#	ARTICLE	IF	CITATIONS
277	Impact of individual intravenous iron preparations on the differentiation of monocytes towards macrophages and dendritic cells. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1835-1845.	0.4	23
278	Janus Face of Coronary Artery Disease and Chronic Kidney Disease. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	5
279	Targeted erythropoietin selectively stimulates red blood cell expansion in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 5245-5250.	3.3	16
280	Intravenous iron administration strategies and anemia management in hemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2016, 32, gfw316.	0.4	8
282	Biosimilars in rheumatic diseases: structural and functional variability that may impact clinical and regulatory decisions. <i>Clinical Rheumatology</i> , 2016, 35, 2869-2875.	1.0	3
283	Biosimilar erythropoiesis-stimulating agents and the risk of developing anti-drug antibodies—a systematic review. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1161-1169.	0.8	1
284	From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals. <i>Clinical and Experimental Immunology</i> , 2016, 184, 137-146.	1.1	76
285	C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2016, 68, 873-881.	2.1	28
286	Novel insights into renovascular hypertension and cardio-renal protection by iron restriction. <i>Hypertension Research</i> , 2016, 39, 829-831.	1.5	0
287	Clinical Perspectives on Targeting Therapies for Personalized Medicine. <i>Advances in Protein Chemistry and Structural Biology</i> , 2016, 102, 79-114.	1.0	6
288	Hemoglobin Concentration and Risk of Incident Stroke in Community-Living Adults. <i>Stroke</i> , 2016, 47, 2017-2024.	1.0	52
289	Commentary on Pharmacotherapy of Hypertension in Patients on Chronic Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 2076-2077.	2.2	0
290	Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 2073-2085.	0.4	2
291	Impact of European medicines agency recommendations for hypersensitivity reactions on intravenous iron prescription in haemodialysis centres of the Lombardy region. <i>Journal of Nephrology</i> , 2016, 29, 673-681.	0.9	8
292	Pure Red Cell Aplasia Following Interleukin-2 Therapy. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2016, 4, 232470961664399.	0.3	2
293	Anemia in type 2 diabetic patients and correlation with kidney function in a tertiary care sub-Saharan African hospital: a cross-sectional study. <i>BMC Nephrology</i> , 2016, 17, 29.	0.8	38
294	Pure red cell aplasia induced by epoetin zeta. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 599-602.	1.4	9
295	Assessing the Immunogenicity of Biopharmaceuticals. <i>BioDrugs</i> , 2016, 30, 195-206.	2.2	89

#	ARTICLE	IF	CITATIONS
296	Balancing the Evidence: How to Reconcile the Results of Observational Studies vs. Randomized Clinical Trials in Dialysis. <i>Seminars in Dialysis</i> , 2016, 29, 342-346.	0.7	2
297	Antihypertensive Medication in Patients Pre- and Postdialysis: Still Hazy After All These Years. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1327-1329.	2.2	0
298	Analysis of the erythropoietin of a Tibetan Plateau schizothoracine fish (<i>Gymnocypris dobula</i>) reveals enhanced cytoprotection function in hypoxic environments. <i>BMC Evolutionary Biology</i> , 2016, 16, 11.	3.2	44
299	Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future. <i>Toxicology and Applied Pharmacology</i> , 2016, 299, 70-77.	1.3	152
300	A prospective observational study of early intervention with erythropoietin therapy and renal survival in non-dialysis chronic kidney disease patients with anemia: JET-STREAM Study. <i>Clinical and Experimental Nephrology</i> , 2016, 20, 885-895.	0.7	13
301	HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. <i>Nature Reviews Nephrology</i> , 2016, 12, 157-168.	4.1	234
302	International Comparisons to Assess Effects of Payment and Regulatory Changes in the United States on Anemia Practice in Patients on Hemodialysis: The Dialysis Outcomes and Practice Patterns Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 2205-2215.	3.0	31
303	Comparative Effects of Metal-Catalyzed Oxidizing Systems on Carbonylation and Integrity of Therapeutic Proteins. <i>Pharmaceutical Research</i> , 2016, 33, 526-539.	1.7	20
304	Safety concerns about intravenous iron therapy in patients with chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 260-267.	1.4	46
305	The American Society of Nephrology at 50. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 369-371.	2.2	1
306	Hypoxia-Inducible Factor Stabilizers: a New Avenue for Reducing BP While Helping Hemoglobin?. <i>Current Hypertension Reports</i> , 2016, 18, 23.	1.5	17
307	Endothelin. <i>Pharmacological Reviews</i> , 2016, 68, 357-418.	7.1	574
308	The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease. <i>Clinical Drug Investigation</i> , 2016, 36, 421-431.	1.1	13
309	Change in quality of life and one-year mortality risk in maintenance dialysis patients. <i>Quality of Life Research</i> , 2016, 25, 2295-2306.	1.5	24
310	Endothelial Progenitor Cell Levels Predict Future Physical Function: An Exploratory Analysis From the VA Enhanced Fitness Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 71, 362-369.	1.7	14
311	Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 3129-3138.	3.0	50
312	Association of Serum Erythropoietin With Cardiovascular Events, Kidney Function Decline, and Mortality. <i>Circulation: Heart Failure</i> , 2016, 9, e002124.	1.6	28
313	Predictive factors associated with increased progression to dialysis in early chronic kidney disease (stage 1-3) patients. <i>Clinical and Experimental Nephrology</i> , 2016, 20, 740-747.	0.7	6

#	ARTICLE	IF	CITATIONS
314	Risk Management for Materials and Components Used in Orally Inhaled and Nasal Drug Products. <i>Pharmaceutical Research</i> , 2016, 33, 1-17.	1.7	33
315	Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 539-546.	2.2	20
316	Biosimilarity Versus Manufacturing Change: Two Distinct Concepts. <i>Pharmaceutical Research</i> , 2016, 33, 261-268.	1.7	39
317	Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 287-301.	1.5	30
318	Impact of hemoglobin levels on renal and non-renal clinical outcomes differs by chronic kidney disease stages: the Gonryo study. <i>Clinical and Experimental Nephrology</i> , 2016, 20, 595-602.	0.7	17
319	Excess mortality attributable to chronic kidney disease. Results from the PIRP project. <i>Journal of Nephrology</i> , 2016, 29, 663-671.	0.9	10
320	Four-Week Studies of Oral Hypoxia-Inducible Factor-1 Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1234-1244.	3.0	166
321	Roles of renal erythropoietin-producing (REP) cells in the maintenance of systemic oxygen homeostasis. <i>Pflügers Archiv European Journal of Physiology</i> , 2016, 468, 3-12.	1.3	54
322	Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial). <i>Clinical and Experimental Nephrology</i> , 2016, 20, 71-76.	0.7	7
323	Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia—the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). <i>Journal of Human Hypertension</i> , 2016, 30, 46-52.	1.0	13
324	Longitudinal trends in serum ferritin levels and associated factors in a national incident hemodialysis cohort. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 370-377.	0.4	11
325	Biosimilars in rheumatology: understanding the rigor of their development. <i>Rheumatology</i> , 2017, 56, 187-197.	0.9	30
326	Renal Anemia Model Mouse Established by Transgenic Rescue with an Erythropoietin Gene Lacking Kidney-Specific Regulatory Elements. <i>Molecular and Cellular Biology</i> , 2017, 37, .	1.1	20
327	Facility Practice Variation to Help Understand the Effects of Public Policy: Insights from the Dialysis Outcomes and Practice Patterns Study (DOPPS). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 190-199.	2.2	12
328	Erythropoiesis stimulating agents and reno-protection: a meta-analysis. <i>BMC Nephrology</i> , 2017, 18, 14.	0.8	38
329	Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1851-1858.	3.0	92
330	A retrospective open-label uncontrolled study of Epoetin zeta on the treatment of chemotherapy-induced anemia in solid tumors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 717-725.	1.2	3
331	Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 355-363.	0.5	246

#	ARTICLE	IF	CITATIONS
332	Restricted Use of Erythropoiesis-Stimulating Agent is Safe and Associated with Deferred Dialysis Initiation in Stage 5 Chronic Kidney Disease. <i>Scientific Reports</i> , 2017, 7, 44013.	1.6	6
333	Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 22-32.	1.4	7
334	The Obesity Paradox in Kidney Disease: How to Reconcile It With Obesity Management. <i>Kidney International Reports</i> , 2017, 2, 271-281.	0.4	124
335	Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 38.	0.7	20
336	The Use of Darbepoetin to Stimulate Erythropoiesis in the Treatment of Anemia of Chronic Kidney Disease in Dogs. <i>Journal of Veterinary Internal Medicine</i> , 2017, 31, 476-485.	0.6	12
337	History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology. <i>American Journal of Nephrology</i> , 2017, 45, 235-247.	1.4	814
339	The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries. <i>Advances in Therapy</i> , 2017, 34, 1128-1144.	1.3	64
340	Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies. <i>Experimental Cell Research</i> , 2017, 356, 160-165.	1.2	44
341	Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy. <i>BMJ Open</i> , 2017, 7, e011637.	0.8	22
342	Erythropoietin Hyporesponsiveness in Dialysis Patients: Possible Role of Statins. <i>American Journal of Nephrology</i> , 2017, 46, 11-17.	1.4	15
343	Clinical Trial Design in Juvenile Idiopathic Arthritis. <i>Paediatric Drugs</i> , 2017, 19, 379-389.	1.3	17
344	Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician. <i>Current Rheumatology Reports</i> , 2017, 19, 37.	2.1	79
345	Risk Factors for Heart Failure in Patients With Chronic Kidney Disease: The CRIC (Chronic Renal Infection Trial) Study. <i>Clinical Journal of the American Society of Nephrology</i> , 2017, 10, 1055-1065.	1.6	65
346	Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey. <i>BMJ Open</i> , 2017, 7, e016730.	0.8	41
347	Renal association clinical practice guideline in post-operative care in the kidney transplant recipient. <i>BMC Nephrology</i> , 2017, 18, 174.	0.8	126
348	Role of B-type Natriuretic Peptide and N-terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	75
349	Medication adherence in randomized controlled trials evaluating cardiovascular or mortality outcomes in dialysis patients: A systematic review. <i>BMC Nephrology</i> , 2017, 18, 42.	0.8	27
350	Safety of intravenous iron in hemodialysis patients. <i>Hemodialysis International</i> , 2017, 21, S93-S103.	0.4	17

#	ARTICLE	IF	CITATIONS
351	Choosing Wisely. Canadian Journal of Kidney Health and Disease, 2017, 4, 205435811769557.	0.6	7
352	Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation, 2017, 32, 1373-1386.	0.4	159
353	Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study. BMC Nephrology, 2017, 18, 97.	0.8	9
354	Overview of iron metabolism in health and disease. Hemodialysis International, 2017, 21, S6-S20.	0.4	288
355	Pilot study of the effect of cholecalciferol supplementation on hepcidin in children with chronic kidney disease: Results of the D-fense Trial. Pediatric Nephrology, 2017, 32, 859-868.	0.9	9
356	A novel combination of four flavonoids derived from Astragali Radix relieves the symptoms of cyclophosphamide-induced anemic rats. FEBS Open Bio, 2017, 7, 318-323.	1.0	24
357	The process defines the product: what really matters in biosimilar design and production?. Rheumatology, 2017, 56, iv14-iv29.	0.9	110
358	Action plan for optimizing the design of clinical trials in chronic kidney disease. Kidney International Supplements, 2017, 7, 138-144.	4.6	19
359	Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action. Kidney International Supplements, 2017, 7, 122-129.	4.6	106
360	Delivery of human erythropoietin gene with an adeno-associated virus vector through parotid glands to treat renal anaemia in a swine model. Gene Therapy, 2017, 24, 692-698.	2.3	5
361	EV-3, an endogenous human erythropoietin isoform with distinct functional relevance. Scientific Reports, 2017, 7, 3684.	1.6	20
362	Levodopa Injections Decrease the Need for Erythropoiesis-Stimulating Agents in Hemodialysis Patients with Renal Anemia. CardioRenal Medicine, 2017, 7, 188-197.	0.7	16
363	The Medicare Access and CHIP Reauthorization Act: Implications for Nephrology. Journal of the American Society of Nephrology: JASN, 2017, 28, 2590-2596.	3.0	13
364	Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease. The Cochrane Library, 2017, 8, CD009904.	1.5	17
365	Optimal hematocrit in an artificial microvascular network. Transfusion, 2017, 57, 2257-2266.	0.8	13
366	Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. American Journal of Nephrology, 2017, 46, 488-497.	1.4	8
367	New options for the anemia of chronic kidney disease. Kidney International Supplements, 2017, 7, 157-163.	4.6	35
368	Discovery of JTZ-951: A HIF Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia. ACS Medicinal Chemistry Letters, 2017, 8, 1320-1325.	1.3	43

#	ARTICLE	IF	CITATIONS
369	Interactive Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers or Their Combination on Survival of Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2017, 46, 439-447.	1.4	6
370	Pre-End-Stage Renal Disease Hemoglobin Variability Predicts Post-End-Stage Renal Disease Mortality in Patients Transitioning to Dialysis. <i>American Journal of Nephrology</i> , 2017, 46, 397-407.	1.4	16
371	Real-World Impact of Cardiovascular Disease and Anemia on Quality of Life and Productivity in Patients with Non-Dialysis-Dependent Chronic Kidney Disease. <i>Advances in Therapy</i> , 2017, 34, 1662-1672.	1.3	40
372	Individualized drug dosing using RBF-Galerkin method: Case of anemia management in chronic kidney disease. <i>Computer Methods and Programs in Biomedicine</i> , 2017, 148, 45-53.	2.6	10
373	Emerging biologics in inflammatory bowel disease. <i>Journal of Gastroenterology</i> , 2017, 52, 141-150.	2.3	67
374	Intravenous iron and erythropoiesis-stimulating agents in haemodialysis: A systematic review and meta-analysis. <i>Nephrology</i> , 2017, 22, 969-976.	0.7	26
375	Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia. <i>Antioxidants and Redox Signaling</i> , 2017, 26, 718-742.	2.5	291
376	The effect of altitude on erythropoiesis-stimulating agent dose, hemoglobin level, and mortality in hemodialysis patients. <i>Journal of Nephrology</i> , 2017, 30, 821-829.	0.9	8
377	Practical considerations for iron therapy in the management of anaemia in patients with chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2017, 10, i9-i15.	1.4	14
378	A central role for hypoxia-inducible factor (HIF)-2 β in hepatic glucose homeostasis. <i>Nutrition and Healthy Aging</i> , 2017, 4, 207-216.	0.5	33
379	A threshold trajectory was revealed by isolating the effects of hemoglobin rate of rise in anemia of chronic kidney disease. <i>Therapeutic Advances in Drug Safety</i> , 2017, 8, 305-318.	1.0	2
380	β -klotho and anemia in patients with chronic kidney disease patients: A new perspective (Review). <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 5691-5695.	0.8	10
381	Chronic kidney disease-associated cardiovascular disease: scope and limitations of animal models. <i>Cardiovascular Endocrinology</i> , 2017, 6, 120-127.	0.8	5
382	T-cell assays confirm immunogenicity of tungsten-induced erythropoietin aggregates associated with pure red cell aplasia. <i>Blood Advances</i> , 2017, 1, 367-379.	2.5	27
383	The influence of direct laser metal sintering implants on the early stages of osseointegration in diabetic mini-pigs. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 5433-5442.	3.3	12
384	Why the Immune System Should Be Concerned by Nanomaterials?. <i>Frontiers in Immunology</i> , 2017, 8, 544.	2.2	59
385	Epoetin Alfa: A Cause of Coronary Artery Thrombosis. <i>Case Reports in Cardiology</i> , 2017, 2017, 1-4.	0.1	0
386	High Levels of Hemoglobin Promote Carotid Adventitial Vasa Vasorum Neoangiogenesis in Chronic Kidney Disease. <i>Mediators of Inflammation</i> , 2017, 2017, 1-11.	1.4	5

#	ARTICLE	IF	CITATIONS
387	Main Quality Attributes of Monoclonal Antibodies and Effect of Cell Culture Components. Iranian Biomedical Journal, 2017, 21, 131-141.	0.4	51
388	Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon [®] and Eprex [®] following a single subcutaneous administration in healthy male volunteers. Drug Design, Development and Therapy, 2017, Volume 11, 3127-3135.	2.0	7
389	Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial. PLoS ONE, 2017, 12, e0172735.	1.1	12
390	Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks. PLoS ONE, 2017, 12, e0182613.	1.1	91
391	Predictors of adherence to a new erythropoiesis-stimulating agent inpatient ordering policy: A cross-sectional study. PLoS ONE, 2017, 12, e0188390.	1.1	0
392	Indole 3-acetic acid, indoxyl sulfate and paracresyl-sulfate do not influence anemia parameters in hemodialysis patients. BMC Nephrology, 2017, 18, 251.	0.8	14
393	Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrology, 2017, 18, 345.	0.8	179
394	Early winners and losers in dialysis center pay-for-performance. BMC Health Services Research, 2017, 17, 816.	0.9	12
395	Treatment of renal anemia: Erythropoiesis stimulating agents and beyond. Kidney Research and Clinical Practice, 2017, 36, 209-223.	0.9	23
396	HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience. Drug Design, Development and Therapy, 2018, Volume 12, 9-14.	2.0	3
397	Evaluation of the safety and immunogenicity of subcutaneous HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in predialysis and dialysis patients. Clinical Nephrology, 2017, 88, 190-197.	0.4	10
398	Variability in hemoglobin levels in hemodialysis patients in the current era: a retrospective cohort study. Clinical Nephrology, 2017, 88, 254-265.	0.4	8
399	Safety of Intravenous Iron in Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 457-467.	2.2	62
400	Generic Substitution of Orphan Drugs for the Treatment of Rare Diseases: Exploring the Potential Challenges. Drugs, 2018, 78, 399-410.	4.9	8
401	Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?. Clinical Drug Investigation, 2018, 38, 481-490.	1.1	24
402	Hemodialysis-induced cardiovascular disease. Seminars in Dialysis, 2018, 31, 258-267.	0.7	97
403	Computational design and experimental characterization of a novel β^2 -common receptor inhibitory peptide. Peptides, 2018, 104, 1-6.	1.2	2
404	Mitochondrial dysfunction in diabetic kidney disease. Nature Reviews Nephrology, 2018, 14, 291-312.	4.1	345

#	ARTICLE	IF	CITATIONS
405	Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained. <i>BioDrugs</i> , 2018, 32, 129-135.	2.2	17
406	The Concept of Biosimilars: From Characterization to Evolution—A Narrative Review. <i>Oncologist</i> , 2018, 23, 346-352.	1.9	26
407	Changes in Excess Mortality from End Stage Renal Disease in the United States from 1995 to 2013. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 91-99.	2.2	84
408	Medical safety in the care of the person with end-stage kidney disease. <i>Seminars in Dialysis</i> , 2018, 31, 140-148.	0.7	5
409	An Emerging Treatment Alternative for Anemia in Chronic Kidney Disease Patients: A Review of Daprodustat. <i>Advances in Therapy</i> , 2018, 35, 5-11.	1.3	9
410	Erythropoietin as an add-on treatment for cognitive side effects of electroconvulsive therapy: a study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 234.	0.7	7
411	Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future. <i>Dermatology and Therapy</i> , 2018, 8, 173-194.	1.4	45
412	Early renoprotection by anemia correction. <i>Clinical and Experimental Nephrology</i> , 2018, 22, 1229-1229.	0.7	1
413	Anemia in chronic kidney disease. <i>Pediatric Nephrology</i> , 2018, 33, 227-238.	0.9	65
414	Survival in children requiring chronic renal replacement therapy. <i>Pediatric Nephrology</i> , 2018, 33, 585-594.	0.9	37
415	Comparing the Effectiveness of Dynamic Treatment Strategies Using Electronic Health Records: An Application of the Parametric Gompertz Formula to Anemia Management Strategies. <i>Health Services Research</i> , 2018, 53, 1900-1918.	1.0	26
416	Rationale and design of observational clinical research in chronic kidney disease patients with renal anemia: renal prognosis in patients with hyporesponsive anemia to erythropoiesis-stimulating agents, darbepoetin alfa (BRIGHTEN Trial). <i>Clinical and Experimental Nephrology</i> , 2018, 22, 78-84.	0.7	6
417	Association of the frequency of pre-end-stage renal disease medical care with post-end-stage renal disease mortality and hospitalization. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 789-795.	0.4	6
418	Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 234-240.	0.5	107
419	Expansion of EPOR-negative macrophages besides erythroblasts by elevated EPOR signaling in erythrocytosis mouse models. <i>Haematologica</i> , 2018, 103, 40-50.	1.7	30
420	Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 420-427.	1.3	70
421	De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease. <i>Pediatric Nephrology</i> , 2018, 33, 125-137.	0.9	7
422	Concise Review: Advanced Cell Culture Models for Diamond Blackfan Anemia and Other Erythroid Disorders. <i>Stem Cells</i> , 2018, 36, 172-179.	1.4	17

#	ARTICLE	IF	CITATIONS
423	Anemia as a risk factor for all-cause mortality: obscure synergic effect of chronic kidney disease. <i>Clinical and Experimental Nephrology</i> , 2018, 22, 388-394.	0.7	26
424	Visual-Evoked-Response-Supported Outcome of Intravitreal Erythropoietin in Management of Indirect Traumatic Optic Neuropathy. <i>Journal of Ophthalmology</i> , 2018, 2018, 1-9.	0.6	9
425	Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006–2015). <i>BMC Nephrology</i> , 2018, 19, 318.	0.8	24
426	Red blood cell volume is not decreased in ESA-naive anemic chronic kidney disease patients. <i>Physiological Reports</i> , 2018, 6, e13900.	0.7	7
427	Effects of recombinant human erythropoietin on cognition and neural activity in remitted patients with mood disorders and first-degree relatives of patients with psychiatric disorders: a study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 611.	0.7	16
428	Established and Emerging Concepts to Treat Imbalances of Iron Homeostasis in Inflammatory Diseases. <i>Pharmaceuticals</i> , 2018, 11, 135.	1.7	29
429	Hemoglobin targets for the anemia in patients with dialysis-dependent chronic kidney disease: a meta-analysis of randomized, controlled trials. <i>Renal Failure</i> , 2018, 40, 671-679.	0.8	14
430	Perfluoroalkyl substances and kidney function in chronic kidney disease, anemia, and diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2018, Volume 11, 707-716.	1.1	36
431	Predialysis anemia management and outcomes following dialysis initiation: A retrospective cohort analysis. <i>PLoS ONE</i> , 2018, 13, e0203767.	1.1	8
432	Partnership for productive development of biosimilar products: perspectives of access to biological products in the Brazilian market. <i>Einstein (Sao Paulo, Brazil)</i> , 2018, 16, eRW4175.	0.3	5
433	Personalized ESA doses for anemia management in hemodialysis patients with end-stage renal disease. <i>System Dynamics Review</i> , 2018, 34, 121-153.	1.1	17
434	Association of Anemia and Iron Parameters With Mortality Among Patients Undergoing Prevalent Hemodialysis in Taiwan: The AIM-HD Study. <i>Journal of the American Heart Association</i> , 2018, 7, e009206.	1.6	21
435	Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach. <i>Frontiers in Physiology</i> , 2018, 9, 1294.	1.3	103
436	The Evolution of Biosimilars in Oncology, with a Focus on Trastuzumab. <i>Current Oncology</i> , 2018, 25, 171-179.	0.9	28
437	Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2018, 48, 251-259.	1.4	11
438	Evaluating the Evidence behind Policy Mandates in US Dialysis Care. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2777-2779.	3.0	7
439	The anaemia control model: Does it help nephrologists in therapeutic decision-making in the management of anaemia?. <i>Nefrologia</i> , 2018, 38, 491-502.	0.2	9
440	Protective Role of Histidine Supplementation Against Oxidative Stress Damage in the Management of Anemia of Chronic Kidney Disease. <i>Pharmaceuticals</i> , 2018, 11, 111.	1.7	51

#	ARTICLE	IF	CITATIONS
441	Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data. American Journal of Nephrology, 2018, 48, 260-268.	1.4	30
442	Fragmentation of a Monoclonal Antibody by Peroxotungstate. Pharmaceutical Research, 2018, 35, 219.	1.7	7
443	Diabetic nephropathy: newer therapeutic perspectives. Journal of Community Hospital Internal Medicine Perspectives, 2018, 8, 200-207.	0.4	39
444	Evaluation of variables associated with the patency of arteriovenous fistulas for hemodialysis created by a nephrologist. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2018, 40, 326-332.	0.4	3
445	Perspective: Will We Ever Know the Optimal Hgb Level in ESRD?. Journal of the American Society of Nephrology: JASN, 2018, 29, 2454-2457.	3.0	4
446	Switching from Epoetin Alfa (Epogen [®]) to Epoetin Alfa-Epbx (Retacrit [®] ;TM [®]) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis. American Journal of Nephrology, 2018, 48, 214-224.	1.4	7
447	Recommendations on RBC Transfusion in General Critically Ill Children Based on Hemoglobin and/or Physiologic Thresholds From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative. Pediatric Critical Care Medicine, 2018, 19, S98-S113.	0.2	47
448	Shifting ground and gaps in transfusion support of patients with hematological malignancies. Hematology American Society of Hematology Education Program, 2018, 2018, 553-560.	0.9	2
449	Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction. Drug Safety, 2018, 41, 1013-1022.	1.4	38
450	Development and 10-year history of a biosimilar: the example of Binocrit [®] . Therapeutic Advances in Medical Oncology, 2018, 10, 175883591876841.	1.4	6
451	Quality of care and practice patterns in anaemia management at specialist kidney clinics in Ireland: a national study. CKJ: Clinical Kidney Journal, 2018, 11, 99-107.	1.4	18
452	Erythropoietin Treatment Ameliorates Lupus Nephritis of MRL/lpr Mice. Inflammation, 2018, 41, 1888-1899.	1.7	7
453	A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy. Arthritis Research and Therapy, 2018, 20, 155.	1.6	45
454	Anemia and mortality in patients with nondialysis-dependent chronic kidney disease. BMC Nephrology, 2018, 19, 135.	0.8	11
455	Measurement properties of the Short Form-36 (SF-36) and the Functional Assessment of Cancer Therapy - Anemia (FACT-An) in patients with anemia associated with chronic kidney disease. Health and Quality of Life Outcomes, 2018, 16, 111.	1.0	23
456	Activation of the α_2 -common receptor by erythropoietin impairs acetylcholine-mediated vasodilation in mouse mesenteric arterioles. Physiological Reports, 2018, 6, e13751.	0.7	3
457	Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts. Haematologica, 2018, 103, 1593-1603.	1.7	49
458	The Incidence and Pathophysiology of the Obesity Paradox: Should Peritoneal Dialysis and Kidney Transplant Be Offered to Patients with Obesity and End-Stage Renal Disease?. Current Hypertension Reports, 2018, 20, 84.	1.5	10

#	ARTICLE	IF	CITATIONS
459	Aggregates of IVIG or Avastin, but not HSA, modify the response to model innate immune response modulating impurities. <i>Scientific Reports</i> , 2018, 8, 11477.	1.6	25
460	Iron deficiency associates with deterioration in several symptoms independently from hemoglobin level among chronic hemodialysis patients. <i>PLoS ONE</i> , 2018, 13, e0201662.	1.1	15
461	Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis. <i>International Urology and Nephrology</i> , 2018, 50, 2201-2206.	0.6	10
462	Prevalence and predictors of blood transfusion after pediatric kidney transplantation. <i>Pediatric Nephrology</i> , 2018, 33, 2177-2184.	0.9	5
463	Controlling the Glycosylation Profile in mAbs Using Time-Dependent Media Supplementation. <i>Antibodies</i> , 2018, 7, 1.	1.2	29
464	Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2018, 19, 389.	1.8	65
465	Rational Management of Iron-Deficiency Anaemia in Inflammatory Bowel Disease. <i>Nutrients</i> , 2018, 10, 82.	1.7	43
466	Prevalence, treatment patterns, and healthcare resource utilization in Medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States. <i>BMC Nephrology</i> , 2018, 19, 67.	0.8	43
467	Iron metabolism in critically ill patients developing anemia of inflammation: a case control study. <i>Annals of Intensive Care</i> , 2018, 8, 56.	2.2	20
468	SF3B1 deficiency impairs human erythropoiesis via activation of p53 pathway: implications for understanding of ineffective erythropoiesis in MDS. <i>Journal of Hematology and Oncology</i> , 2018, 11, 19.	6.9	35
469	Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives. <i>Journal of Inflammation Research</i> , 2018, Volume 11, 215-226.	1.6	100
470	Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies. <i>Advances in Therapy</i> , 2018, 35, 1295-1332.	1.3	25
471	Decline of kidney function during the pre-dialysis period in chronic kidney disease patients: a systematic review and meta-analysis. <i>Clinical Epidemiology</i> , 2018, Volume 10, 613-622.	1.5	11
472	Cell-free protein synthesis as a novel tool for directed glycoengineering of active erythropoietin. <i>Scientific Reports</i> , 2018, 8, 8514.	1.6	31
473	A novel approach to adenine-induced chronic kidney disease associated anemia in rodents. <i>PLoS ONE</i> , 2018, 13, e0192531.	1.1	60
474	El modelo de control de anemia: ¿ayuda al nefrólogo en la decisión terapéutica para el manejo de la anemia?. <i>Nefrología</i> , 2018, 38, 491-502.	0.2	8
475	Transfusion Management of Incident Dialysis Patients in Canada: A Prospective Observational Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2018, 5, 205435811877856.	0.6	6
476	Medication Safety Principles and Practice in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1738-1746.	2.2	66

#	ARTICLE	IF	CITATIONS
477	Usefulness of mid-week hemoglobin measurement for anemia management in patients undergoing hemodialysis: a retrospective cohort study. <i>BMC Nephrology</i> , 2019, 20, 295.	0.8	1
478	Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease. <i>Kidney International Reports</i> , 2019, 4, 1235-1247.	0.4	3
479	Biosimilars in dermatology: The wind of change (Review). <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 911-915.	0.8	9
480	Recombinant Human Erythropoietin Restrains Oxidative Stress in Streptozotocin-induced Diabetic Rats Exposed to Renal Ischemia Reperfusion Injury. <i>Transplantation Proceedings</i> , 2019, 51, 2076-2080.	0.3	2
481	A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1495-1504.	3.0	53
482	Hemodialysis Quality Metrics in the First Year Following a Failed Kidney Transplant. <i>American Journal of Nephrology</i> , 2019, 50, 161-167.	1.4	14
483	The effect of maintaining high hemoglobin levels on long-term kidney function in kidney transplant recipients: a randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1409-1416.	0.4	28
484	Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3264.	1.8	93
485	Oxygen sensing and adaptability won the 2019 Nobel Prize in Physiology or medicine. <i>Genes and Diseases</i> , 2019, 6, 328-332.	1.5	44
486	Trajectories of Haemoglobin and incident stroke risk: a longitudinal cohort study. <i>BMC Public Health</i> , 2019, 19, 1395.	1.2	9
487	Alteration of the DNA Methylation Signature of Renal Erythropoietin-Producing Cells Governs the Sensitivity to Drugs Targeting the Hypoxia-Response Pathway in Kidney Disease Progression. <i>Frontiers in Genetics</i> , 2019, 10, 1134.	1.1	13
488	The association of the difference in hemoglobin levels before and after hemodialysis with the risk of 1-year mortality in patients undergoing hemodialysis. Results from a nationwide cohort study of the Japanese Renal Data Registry. <i>PLoS ONE</i> , 2019, 14, e0210533.	1.1	2
489	The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy. <i>Biomolecules</i> , 2019, 9, 410.	1.8	48
490	Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy. <i>Advances in Therapy</i> , 2019, 36, 3253-3264.	1.3	11
491	Are Biosimilars the Future of Oncology and Haematology?. <i>Drugs</i> , 2019, 79, 1609-1624.	4.9	10
492	Will There Be a Role for a Short-Acting Biosimilar Erythropoiesis-Stimulating Agent in US Nephrology Practice?. <i>Kidney International Reports</i> , 2019, 4, 1199-1202.	0.4	0
493	Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification. <i>Kidney International Reports</i> , 2019, 4, 1585-1597.	0.4	21
494	Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies. <i>Kidney Medicine</i> , 2019, 1, 271-280.	1.0	2

#	ARTICLE	IF	CITATIONS
495	Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience. <i>Advances in Chronic Kidney Disease</i> , 2019, 26, 253-266.	0.6	135
496	High hemoglobin is associated with increased in-hospital death in patients with chronic obstructive pulmonary disease and chronic kidney disease: a retrospective multicenter population-based study. <i>BMC Pulmonary Medicine</i> , 2019, 19, 174.	0.8	9
497	Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies. <i>BMJ Open</i> , 2019, 9, e026602.	0.8	18
498	Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective. <i>Frontiers in Pharmacology</i> , 2018, 9, 1498.	1.6	18
499	Immunogenicity of Protein Pharmaceuticals. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 1637-1654.	1.6	80
500	A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial. <i>American Journal of Nephrology</i> , 2019, 49, 165-174.	1.4	62
501	Readability assessment of package leaflets of biosimilars. <i>BMJ Open</i> , 2019, 9, e024837.	0.8	4
502	Buttonhole versus Stepladder Cannulation for Home Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 403-410.	2.2	10
503	Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. <i>BMJ Open</i> , 2019, 9, e026704.	0.8	22
504	Adsorption of recombinant human erythropoietin and protein impurities on a multimodal chromatography membrane. <i>Chemical Papers</i> , 2019, 73, 1805-1811.	1.0	4
505	Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study. <i>PLoS Medicine</i> , 2019, 16, e1002818.	3.9	16
506	Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review. <i>Advances in Therapy</i> , 2019, 36, 1851-1877.	1.3	27
507	Cardiorenal Syndrome. <i>Cardiology Clinics</i> , 2019, 37, 251-265.	0.9	88
508	Fatigue in Nondialysis Chronic Kidney Disease: Correlates and Association with Kidney Outcomes. <i>American Journal of Nephrology</i> , 2019, 50, 37-47.	1.4	31
509	High sensitivity Troponin-I levels in asymptomatic hemodialysis patients. <i>Renal Failure</i> , 2019, 41, 393-400.	0.8	17
510	Characterization of erythropoietin biosimilars using mass spectrometric CID and HCD techniques. <i>Journal of Liquid Chromatography and Related Technologies</i> , 2019, 42, 380-391.	0.5	0
511	Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial. <i>Nephron</i> , 2019, 143, 77-85.	0.9	36
512	Erythropoiesis-Stimulating Agents and Mortality. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 907-908.	3.0	12

#	ARTICLE	IF	CITATIONS
513	The biosimilar pathway in the USA: An analysis of the innovator company and biosimilar company perspectives and beyond. <i>Journal of Food and Drug Analysis</i> , 2019, 27, 671-678.	0.9	7
514	Associations of Common Variants in <i>HFE</i> and <i>TMPRSS6</i> Genes with Hepcidin-25 and Iron Status Parameters in Patients with End-Stage Renal Disease. <i>Disease Markers</i> , 2019, 2019, 1-10.	0.6	5
515	Quality of life among patients with moderate to advanced chronic kidney disease in Ghana - a single centre study. <i>BMC Nephrology</i> , 2019, 20, 122.	0.8	31
516	Proteogenomic Annotation of Chinese Hamsters Reveals Extensive Novel Translation Events and Endogenous Retroviral Elements. <i>Journal of Proteome Research</i> , 2019, 18, 2433-2445.	1.8	15
517	Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54. <i>RMD Open</i> , 2019, 5, e000876.	1.8	18
518	Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1037-1048.	3.0	76
519	The interaction between post-transplant anemia and allograft function in kidney transplantation: The Japan Academic Consortium of Kidney Transplantation-II study. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 1066-1075.	0.7	5
520	Biosimilars: An Approach to some Current Worldwide Regulation Frameworks. <i>Current Clinical Pharmacology</i> , 2019, 14, 16-40.	0.2	2
521	Physicochemical characterization and phase I study of CMAB008, an infliximab biosimilar produced by a different expression system. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 791-805.	2.0	9
522	Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing. <i>BMC Nephrology</i> , 2019, 20, 76.	0.8	8
523	Erythropoietin, a multifaceted protein with innate and adaptive immune modulatory activity. <i>American Journal of Transplantation</i> , 2019, 19, 2407-2414.	2.6	46
524	Ethnic prevalence of anemia and predictors of anemia among chronic kidney disease patients at a tertiary hospital in Johannesburg, South Africa. <i>International Journal of Nephrology and Renovascular Disease</i> , 2019, Volume 12, 19-32.	0.8	12
525	Economic Burden and Health-Related Quality of Life Associated with Current Treatments for Anaemia in Patients with CKD not on Dialysis: A Systematic Review. <i>PharmacoEconomics - Open</i> , 2019, 3, 463-478.	0.9	18
526	Effects of high-volume online mixed-hemodiafiltration on anemia management in dialysis patients. <i>PLoS ONE</i> , 2019, 14, e0212795.	1.1	12
527	Comparison of Clopidogrel and Ticlopidine/Ginkgo Biloba in Patients With Clopidogrel Resistance and Carotid Stenting. <i>Frontiers in Neurology</i> , 2019, 10, 44.	1.1	5
528	Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 129-138.	1.4	63
529	Haemoglobin concentration and survival of haemodialysis patients before and after experiencing cardiovascular disease: a cohort study from Japanese dialysis outcomes and practice pattern study (J-DOPPS). <i>BMJ Open</i> , 2019, 9, e031476.	0.8	3
530	Prolyl hydroxylase domain inhibitors: a new era in the management of renal anemia. <i>Annals of Translational Medicine</i> , 2019, 7, S334-S334.	0.7	4

#	ARTICLE	IF	CITATIONS
531	Authorsâ€™ Reply. Journal of the American Society of Nephrology: JASN, 2019, 30, 1773-1776.	3.0	0
532	Now a Nobel gas: oxygen. Pflugers Archiv European Journal of Physiology, 2019, 471, 1343-1358.	1.3	39
533	SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481989108.	1.4	11
534	Pure red cell aplasia and anti-erythropoietin antibodies in patients on hemodialysis: a report of two cases and a literature review. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2019, 41, 145-151.	0.4	5
535	Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan. Clinical and Experimental Nephrology, 2019, 23, 231-243.	0.7	9
536	Impact of Recent Clinical Trials on Nephrology Practice: Are We in a Stagnant Era?. Kidney Diseases (Basel, Switzerland), 2019, 5, 69-80.	1.2	10
537	Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 2019, 73, 309-315.	2.1	18
538	Potential use of transgenic domestic pigs expressing recombinant human erythropoietin in diabetes translation research. Animal Cells and Systems, 2019, 23, 42-49.	0.8	4
539	Achievement of renal anemia KDIGO targets by two different clinical strategies â€” a European hemodialysis multicenter analysis. BMC Nephrology, 2019, 20, 5.	0.8	7
540	Compatibility of rubber stoppers for recombinant antitumor-antivirus protein injection by gas chromatography-mass spectrometry. Journal of Pharmaceutical Analysis, 2019, 9, 178-184.	2.4	4
541	Effect of achieved hemoglobin level on renal outcome in non-dialysis chronic kidney disease (CKD) patients receiving epoetin beta pegol: MIRcerA CLinical Evidence on Renal Survival in CKD patients with renal anemia (MIRACLE-CKD Study). Clinical and Experimental Nephrology, 2019, 23, 349-361.	0.7	13
542	Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. CKJ: Clinical Kidney Journal, 2019, 12, 139-148.	1.4	87
543	Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents. Nephrology Dialysis Transplantation, 2019, 34, 90-99.	0.4	62
544	Measurement of iron status in chronic kidney disease. Pediatric Nephrology, 2019, 34, 605-613.	0.9	18
545	Trends in the treatment of chronic kidney disease-associated anaemia in a cohort of haemodialysis patients: the Irish experience. Irish Journal of Medical Science, 2019, 188, 223-230.	0.8	8
546	The multifaceted role of iron in renal health and disease. Nature Reviews Nephrology, 2020, 16, 77-98.	4.1	167
547	Low hemoglobin at hemodialysis initiation: an international study of anemia management and mortality in the early dialysis period. CKJ: Clinical Kidney Journal, 2020, 13, 425-433.	1.4	12
548	Anemia and iron deficiency among chronic kidney disease Stages 3â€“5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated. CKJ: Clinical Kidney Journal, 2020, 13, 613-624.	1.4	68

#	ARTICLE	IF	CITATIONS
549	Kidney disease trials for the 21st century: innovations in design and conduct. <i>Nature Reviews Nephrology</i> , 2020, 16, 173-185.	4.1	14
550	Patient-Centred Outcomes in Anaemia and Renal Disease: A Systematic Review. <i>Kidney Diseases (Basel)</i> , 2020, 1, 1-12.	1.0	14
551	Microparticles derived from human erythropoietin mRNA-transfected mesenchymal stem cells inhibit epithelial-to-mesenchymal transition and ameliorate renal interstitial fibrosis. <i>Stem Cell Research and Therapy</i> , 2020, 11, 422.	2.4	7
552	Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era. <i>Kidney Medicine</i> , 2020, 2, 589-599.e1.	1.0	16
553	Interdialytic Weight Gain Effects on Hemoglobin Concentration and Cardiovascular Events. <i>Kidney International Reports</i> , 2020, 5, 1670-1678.	0.4	8
554	Effects of Erythropoietin-Stimulating Agents on Blood Pressure in Patients with Non-Dialysis CKD and Renal Anemia. <i>Kidney Diseases (Basel, Switzerland)</i> , 2020, 6, 299-308.	1.2	3
555	Inflammation and Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients: A Self-matched Longitudinal Study of Anemia Management in the Dialysis Outcomes and Practice Patterns Study (DOPPS). <i>Kidney Medicine</i> , 2020, 2, 286-296.	1.0	21
556	The Impact of CKD Anaemia on Patients: Incidence, Risk Factors, and Clinical Outcomes—A Systematic Literature Review. <i>International Journal of Nephrology</i> , 2020, 2020, 1-21.	0.7	51
557	Differentiation of endogenous erythropoietin and exogenous ESAs by Western blotting. <i>Heliyon</i> , 2020, 6, e05389.	1.4	5
558	Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2039-2048.	0.4	20
559	Erythropoietin receptor in B cells plays a role in bone remodeling in mice. <i>Theranostics</i> , 2020, 10, 8744-8756.	4.6	18
560	The current and future landscape of dialysis. <i>Nature Reviews Nephrology</i> , 2020, 16, 573-585.	4.1	252
561	Associations of cerebral oxygenation with hemoglobin levels evaluated by near-infrared spectroscopy in hemodialysis patients. <i>PLoS ONE</i> , 2020, 15, e0236720.	1.1	10
562	Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview. <i>Biomedicines</i> , 2020, 8, 303.	1.4	2
563	Health technology assessment of biosimilars worldwide: a scoping review. <i>Health Research Policy and Systems</i> , 2020, 18, 95.	1.1	10
564	Knowledge, Attitude, and Practice Towards Biosimilars and Interchangeable Products: A Prescriptive Insight by the Pharmacists. <i>International Journal of General Medicine</i> , 2020, Volume 13, 1075-1082.	0.8	15
565	Population Pharmacodynamic Modeling of Epoetin Alfa in End-Stage Renal Disease Patients Receiving Maintenance Treatment Using Bayesian Approach. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 596-605.	1.3	0
566	Simultaneous management of disordered phosphate and iron homeostasis to correct fibroblast growth factor 23 and associated outcomes in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 359-366.	1.0	6

#	ARTICLE	IF	CITATIONS
567	The prolyl hydroxylase inhibitor roxadustat: Paradigm in drug discovery and prospects for clinical application beyond anemia. <i>Drug Discovery Today</i> , 2020, 25, 1262-1269.	3.2	18
568	Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 821-827.	1.4	29
569	Economic Benefits of Switching From Intravenous to Subcutaneous Epoetin Alfa for the Management of Anemia in Hemodialysis Patients. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812092753.	0.6	2
570	Cerebrovascular Disease and Cognition in Chronic Kidney Disease Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 96.	1.1	39
571	Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, ii38-ii42.	0.4	10
572	Erythropoietin production by the kidney and the liver in response to severe hypoxia evaluated by Western blotting with deglycosylation. <i>Physiological Reports</i> , 2020, 8, e14485.	0.7	14
573	Management of Anemia in Nondialysis Chronic Kidney Disease: Current Recommendations, Real-World Practice, and Patient Perspectives. <i>Kidney360</i> , 2020, 1, 855-862.	0.9	10
574	Effect of Maintenance Intravenous Iron Treatment on Erythropoietin Dose in Chronic Hemodialysis Patients: A Multicenter Randomized Controlled Trial. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812093339.	0.6	2
575	The Many Facets of Erythropoietin Physiologic and Metabolic Response. <i>Frontiers in Physiology</i> , 2019, 10, 1534.	1.3	109
576	Treatment of Neonatal Hypoxic-Ischemic Encephalopathy with Erythropoietin Alone, and Erythropoietin Combined with Hypothermia: History, Current Status, and Future Research. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1487.	1.8	47
577	PPAR β /TLR4/TGF- β 1 axis mediates the protection effect of erythropoietin on cyclosporin A-induced chronic nephropathy in rat. <i>Renal Failure</i> , 2020, 42, 216-224.	0.8	11
578	The Influence of Inflammation on Anemia in CKD Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 725.	1.8	68
579	Gamma-Aminobutyric Acid Increases Erythropoietin by Activation of Citrate Cycle and Stimulation of Hypoxia-Inducible Factors Expression in Rats. <i>Biomolecules</i> , 2020, 10, 595.	1.8	5
580	A longitudinal analysis of the effect of anemia on health-related quality of life in children with mild-to-moderate chronic kidney disease. <i>Pediatric Nephrology</i> , 2020, 35, 1659-1667.	0.9	11
581	Prevalence of anemia in predialysis chronic kidney disease: Is the study center a significant factor?. <i>PLoS ONE</i> , 2020, 15, e0230980.	1.1	12
582	Targeting optimal PD management in children: what have we learned from the IPPN registry?. <i>Pediatric Nephrology</i> , 2021, 36, 1053-1063.	0.9	10
583	The Role of Feedback Control Design in Developing Anemia Management Protocols. <i>Annals of Biomedical Engineering</i> , 2021, 49, 171-179.	1.3	2
584	Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR). <i>EclinicalMedicine</i> , 2021, 31, 100693.	3.2	3

#	ARTICLE	IF	CITATIONS
585	Physiological and pathophysiological mechanisms of hepcidin regulation: clinical implications for iron disorders. <i>British Journal of Haematology</i> , 2021, 193, 882-893.	1.2	37
586	A systematic review and participant-level meta-analysis found little association of retinal microvascular caliber with reduced kidney function. <i>Kidney International</i> , 2021, 99, 696-706.	2.6	8
587	Selective potassium uptake via biocompatible zeoliteâ€“polymer hybrid microbeads as promising binders for hyperkalemia. <i>Bioactive Materials</i> , 2021, 6, 543-558.	8.6	9
588	Control of Anemia in Hemodialysis Patients. , 2021, , 290-298.		0
589	Monitoring the manufacturing and quality of medicines: a fundamental task of pharmacovigilance. <i>Therapeutic Advances in Drug Safety</i> , 2021, 12, 204209862110384.	1.0	19
590	Acquired pure red cell aplasia and recombinant erythropoietin. <i>Indian Journal of Nephrology</i> , 2021, 31, 331.	0.2	1
591	High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis. <i>Cardiovascular Research</i> , 2023, 119, 213-220.	1.8	7
592	The cardiovascularâ€“dialysis nexus: the transition to dialysis is a treacherous time for the heart. <i>European Heart Journal</i> , 2021, 42, 1244-1253.	1.0	14
593	Factors affecting pre-end-stage kidney disease haemoglobin control and outcomes following dialysis initiation: a nationwide study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1780-1788.	1.4	4
594	Self-reported Financial Conflict of Interest in Nephrology Clinical Practice Guidelines. <i>Kidney International Reports</i> , 2021, 6, 768-774.	0.4	5
595	Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 960-972.	0.4	10
597	Roxadustat for CKD-related Anemia in Non-dialysis Patients. <i>Kidney International Reports</i> , 2021, 6, 624-635.	0.4	65
598	The HIF-PHI BAY 85-3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1117-1130.	3.1	16
599	Preparation and characterization of 96-well microplates coated with molecularly imprinted polymer for determination and biosimilarity assessment of recombinant human erythropoietin. <i>Journal of Chromatography A</i> , 2021, 1641, 462012.	1.8	8
601	Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a singleâ€“arm, phase 3 study. <i>Therapeutic Apheresis and Dialysis</i> , 2021, 25, 917-925.	0.4	7
602	Blood Transfusion and Adverse Graft-related Events in Kidney Transplant Patients. <i>Kidney International Reports</i> , 2021, 6, 1041-1049.	0.4	13
604	Opportunities in an Evolving Pharmaceutical Development Landscape: Product Differentiation of Biopharmaceutical Drug Products. <i>Pharmaceutical Research</i> , 2021, 38, 739-757.	1.7	6
605	Temporal Trends in Hemoglobin, Use of Erythropoiesis Stimulating Agents, and Major Clinical Outcomes in Incident Dialysis Patients in Canada. <i>Kidney International Reports</i> , 2021, 6, 1130-1140.	0.4	1

#	ARTICLE	IF	CITATIONS
606	Hypoxia-inducible factor-1 α prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. <i>Kidney International Supplements</i> , 2021, 11, 8-25.	4.6	75
607	The Efficacy and Safety of Switching From Originator Infliximab to Single or Double Switch Biosimilar Among a Nationwide Cohort of Inflammatory Bowel Disease Patients. <i>Crohn's & Colitis</i> 360, 2021, 3, .	0.5	6
608	Anemia management: a historical perspective. <i>Kidney International Supplements</i> , 2021, 11, 3-7.	4.6	2
609	Impairment of human terminal erythroid differentiation by histone deacetylase 5 deficiency. <i>Blood</i> , 2021, 138, 1615-1627.	0.6	26
610	Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES). <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1616-1628.	0.4	76
611	A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study. <i>Kidney International Reports</i> , 2021, 6, 1840-1849.	0.4	22
612	Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKD. <i>Kidney International Reports</i> , 2021, 6, 1810-1828.	0.4	35
613	miR663 Prevents Epo Inhibition Caused by TNF-Alpha in Normoxia and Hypoxia. <i>International Journal of Endocrinology</i> , 2021, 2021, 1-10.	0.6	2
615	Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single-arm, open-label, phase 3 study. <i>Therapeutic Apheresis and Dialysis</i> , 2021, , .	0.4	8
616	Differentiating iron-loading anemias using a newly developed and analytically validated ELISA for human serum erythroferrone. <i>PLoS ONE</i> , 2021, 16, e0254851.	1.1	5
617	A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study. <i>Kidney International Reports</i> , 2021, 6, 1829-1839.	0.4	55
618	Challenging patient phenotypes in the management of anaemia of chronic kidney disease. <i>International Journal of Clinical Practice</i> , 2021, 75, e14681.	0.8	5
619	Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial. <i>BMC Nephrology</i> , 2021, 22, 284.	0.8	0
620	Trends in Adaptive Design Methods in Dialysis Clinical Trials: A Systematic Review. <i>Kidney Medicine</i> , 2021, 3, 925-941.	1.0	5
621	Association Between Kidney Clearance of Secretory Solutes and Cardiovascular Events: The Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2021, 78, 226-235.e1.	2.1	7
622	Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1190-1200.	2.2	44
623	Optimization of polydopamine imprinted polymer for label free sensitive potentiometric determination of proteins: Application to recombinant human erythropoietin sensing in different matrices. <i>Microchemical Journal</i> , 2021, 167, 106333.	2.3	12
624	Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES). <i>Advances in Therapy</i> , 2021, 38, 5361-5380.	1.3	48

#	ARTICLE	IF	CITATIONS
625	Epidemiologic and Genetic Associations of Erythropoietin With Blood Pressure, Hypertension, and Coronary Artery Disease. <i>Hypertension</i> , 2021, 78, 1555-1566.	1.3	1
626	Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies. <i>Advances in Therapy</i> , 2021, 38, 5345-5360.	1.3	39
627	Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods. <i>Methods in Molecular Biology</i> , 2022, 2313, 57-113.	0.4	26
628	Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection. <i>Cardiovascular Drugs and Therapy</i> , 2021, , 1.	1.3	11
629	Î±-Klotho gene and protein measurements in humans and their role as a clinical biomarker of disease. , 2021, , 265-298.		0
630	Production and Purification of Therapeutic Enzymes. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1148, 1-24.	0.8	12
631	A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?. <i>Drugs</i> , 2017, 77, 1155-1186.	4.9	27
632	Sequences responsible for the altered erythropoietin responsiveness in spleen focus-forming virus strain SFFVP-infected cells are localized to a 678-base-pair region at the 3' end of the envelope gene. <i>Journal of Virology</i> , 1987, 61, 1661-1664.	1.5	20
633	Hypoxia-Inducible Factor-Proline Hydroxylase Inhibitor in the Treatment of Renal Anemia. <i>Kidney Diseases (Basel, Switzerland)</i> , 2021, 7, 1-9.	1.2	7
634	Laboratory use of hepcidin in renal transplant recipients. <i>Biochemia Medica</i> , 2016, 26, 34-52.	1.2	3
635	Erythroid Precursors in Congenital Hypoplastic (Diamond-Blackfan) Anemia. <i>Journal of Clinical Investigation</i> , 1978, 61, 489-498.	3.9	140
636	The anemia of chronic renal failure in sheep. Response to erythropoietin-rich plasma in vivo.. <i>Journal of Clinical Investigation</i> , 1984, 74, 434-441.	3.9	82
637	Role of endogenous prostaglandin E2 in erythropoietin production and dome formation by human renal carcinoma cells in culture.. <i>Journal of Clinical Investigation</i> , 1984, 74, 1252-1261.	3.9	28
638	Purification and partial characterization of a megakaryocyte colony-stimulating factor from human plasma.. <i>Journal of Clinical Investigation</i> , 1985, 75, 1174-1182.	3.9	76
639	Dependence of highly enriched human bone marrow progenitors on hemopoietic growth factors and their response to recombinant erythropoietin.. <i>Journal of Clinical Investigation</i> , 1986, 77, 74-81.	3.9	93
640	Studies of human megakaryocytopoiesis using an anti-megakaryocyte colony-stimulating factor antiserum.. <i>Journal of Clinical Investigation</i> , 1986, 77, 1873-1880.	3.9	12
641	Purification of human erythroid colony-forming units and demonstration of specific binding of erythropoietin.. <i>Journal of Clinical Investigation</i> , 1987, 80, 357-366.	3.9	203
642	Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney.. <i>Journal of Clinical Investigation</i> , 1988, 81, 620-623.	3.9	391

#	ARTICLE	IF	CITATIONS
643	Hemopoietic colony growth-promoting activities in the plasma of bone marrow transplant recipients.. Journal of Clinical Investigation, 1988, 82, 255-261.	3.9	21
644	Autocrine stimulation by erythropoietin and autonomous growth of human erythroid leukemic cells in vitro.. Journal of Clinical Investigation, 1991, 88, 789-797.	3.9	49
645	Myoblast transfer of human erythropoietin gene in a mouse model of renal failure.. Journal of Clinical Investigation, 1995, 95, 1808-1813.	3.9	78
646	Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. Journal of Clinical Investigation, 2005, 115, 1275-1280.	3.9	370
647	William Kaelin, Peter Ratcliffe, and Gregg Semenza receive the 2016 Albert Lasker Basic Medical Research Award. Journal of Clinical Investigation, 2016, 126, 3628-3638.	3.9	16
648	Erythropoietin regulation of red blood cell production: from bench to bedside and back. F1000Research, 2020, 9, 1153.	0.8	37
649	High-Level Expression of Endo-Î ² -N-Acetylglucosaminidase H from Streptomyces plicatus in Pichia pastoris and Its Application for the Deglycosylation of Glycoproteins. PLoS ONE, 2015, 10, e0120458.	1.1	17
650	The Influence of Artificially Introduced N-Glycosylation Sites on the In Vitro Activity of Xenopus laevis Erythropoietin. PLoS ONE, 2015, 10, e0124676.	1.1	4
651	Predictors and the Subsequent Risk of End-Stage Renal Disease â€œ Usefulness of 30% Decline in Estimated GFR over 2 Years. PLoS ONE, 2015, 10, e0132927.	1.1	36
652	The Korean Clinical Research Center for End-Stage Renal Disease Study Validates the Association of Hemoglobin and Erythropoiesis-Stimulating Agent Dose with Mortality in Hemodialysis Patients. PLoS ONE, 2015, 10, e0140241.	1.1	10
653	The Different Association between Serum Ferritin and Mortality in Hemodialysis and Peritoneal Dialysis Patients Using Japanese Nationwide Dialysis Registry. PLoS ONE, 2015, 10, e0143430.	1.1	27
654	Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients. PLoS ONE, 2016, 11, e0148938.	1.1	25
655	Evaluation of Microflow Digital Imaging Particle Analysis for Sub-Visible Particles Formulated with an Opaque Vaccine Adjuvant. PLoS ONE, 2016, 11, e0150229.	1.1	7
656	Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study. PLoS ONE, 2016, 11, e0155805.	1.1	27
657	Autologous Doping with Cryopreserved Red Blood Cells â€œ Effects on Physical Performance and Detection by Multivariate Statistics. PLoS ONE, 2016, 11, e0156157.	1.1	23
658	Relationship between Hemoglobin Levels Corrected by Interdialytic Weight Gain and Mortality in Japanese Hemodialysis Patients: Miyazaki Dialysis Cohort Study. PLoS ONE, 2017, 12, e0169117.	1.1	11
659	Pure red cell aplasia due to antibody against erythropoietin in hemodialysis patients. Journal of Nephropathology, 2017, 6, 25-29.	0.1	5
660	Associations between erythropoietin polymorphisms and risk of diabetic microvascular complications. Oncotarget, 2017, 8, 112675-112684.	0.8	8

#	ARTICLE	IF	CITATIONS
661	Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin) Tj ETQq0 0,0,rgBT /Overlock 10	3.3	12
662	Understanding the Role of Hypoxia Inducible Factor During Neurodegeneration for New Therapeutics Opportunities. <i>Current Neuropharmacology</i> , 2018, 16, 1484-1498.	1.4	73
663	Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1204-1214.	2.2	18
664	The differential effects of anemia on mortality in young and elderly end-stage renal disease patients. <i>Kidney Research and Clinical Practice</i> , 2020, 39, 192-201.	0.9	3
665	Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up. <i>Kidney Research and Clinical Practice</i> , 2020, 39, 334-343.	0.9	8
666	Obesity may be erythropoietin dose-saving in hemodialysis patients. <i>Kidney Research and Clinical Practice</i> , 2018, 37, 148-156.	0.9	14
667	Current misconceptions in diagnosis and management of iron deficiency. <i>Blood Transfusion</i> , 2017, 15, 422-437.	0.3	83
668	Relationship between Cardiac Geometry and Serum Hepcidin in Chronic Kidney Disease: Analysis from the KNOW-CKD Study. <i>Journal of Korean Medical Science</i> , 2020, 35, e2.	1.1	6
669	Insights on the use of biosimilars in the treatment of inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2017, 23, 1932.	1.4	26
670	Stroke in patients with chronic kidney disease: How do we approach and manage it?. <i>Indian Journal of Nephrology</i> , 2017, 27, 167.	0.2	36
671	Neurotherapeutic potential of erythropoietin after ischemic injury of the central nervous system. <i>Neural Regeneration Research</i> , 2019, 14, 1309.	1.6	37
672	Gender differences in dose of erythropoietin to maintain hemoglobin target in hemodialysis patients. <i>Indian Journal of Nephrology</i> , 2019, 29, 160.	0.2	5
673	Pharmacovigilance of biosimilars – Why is it different from generics and innovator biologics?. <i>Journal of Postgraduate Medicine</i> , 2019, 65, 227-232.	0.2	8
674	Erythropoietin and diabetes mellitus. <i>World Journal of Diabetes</i> , 2015, 6, 1259.	1.3	47
675	Erythropoietin therapy after out-of-hospital cardiac arrest: A systematic review and meta-analysis. <i>World Journal of Cardiology</i> , 2017, 9, 830-837.	0.5	1
676	Long-term treatment with biosimilar epoetin- α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study. <i>Clinical Nephrology</i> , 2018, 89, 1-9.	0.4	7
677	Individualized anemia management in a dialysis facility – long-term utility as a single-center quality improvement experience. <i>Clinical Nephrology</i> , 2018, 90, 276-285.	0.4	15
678	Randomized double-blind clinical trial of a new human epoetin versus a commercially available formula for anemia control in patients on hemodialysis. <i>Clinics</i> , 2014, 69, 547-553.	0.6	2

#	ARTICLE	IF	CITATIONS
679	Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients. American Journal of Nephrology, 2021, 52, 702-713.	1.4	12
680	Improvements in six aspects of quality of care of incident hemodialysis patients – a real-world experience. BMC Nephrology, 2021, 22, 333.	0.8	0
681	All vials are not the same: Potential role of vaccine quality in vaccine adverse reactions. Vaccine, 2021, 39, 6565-6569.	1.7	7
682	Contemporary outcomes of anemia in US patients with chronic kidney disease. CKJ: Clinical Kidney Journal, 2022, 15, 244-252.	1.4	7
683	Similar Outcomes for Two Anemia Treatment Strategies among Elderly Hemodialysis Patients with Diabetes. Journal of Endocrinology and Diabetes, 2014, 1, .	0.2	0
684	Substitutes of Prescription Medicines - A Review of Concerns Relevant to Doctors and Patients. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, FE01-FE05.	0.8	1
685	The authors' reply. Kidney Research and Clinical Practice, 2018, 37, 310-311.	0.9	0
686	Anemia and the use of antihypertensive medications in hemodialysis patients: multicenter retrospective observational study. Ukrainian Journal of Nephrology and Dialysis, 2019, , 29-38.	0.0	0
687	Testing two (of several) intravenous iron dosing strategies in hemodialysis. Annals of Translational Medicine, 2019, 7, S129-S129.	0.7	0
688	Control of Anemia in Hemodialysis Patients. , 2020, , 1-9.		0
690	The Association between Dialysis Dose and Risk of Cancer Death in Patients Undergoing Hemodialysis: The Q-Cohort Study. Internal Medicine, 2020, 59, 1141-1148.	0.3	3
691	Acquired pure red cell aplasia following recombinant erythropoietin (darbepoetin-alfa) therapy. Indian Journal of Nephrology, 2020, 30, 113.	0.2	3
692	Platelet Abnormalities in CKD and Their Implications for Antiplatelet Therapy. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 155-170.	2.2	24
693	Options for intravenous iron supplementation in hemodialysis patients. Kidney Research and Clinical Practice, 2020, 39, 239-243.	0.9	0
694	Association of tubular solute clearances with the glomerular filtration rate and complications of chronic kidney disease: the Chronic Renal Insufficiency Cohort study. Nephrology Dialysis Transplantation, 2021, 36, 1271-1281.	0.4	9
695	Analysis of the Immunogenicity from <scp>Abatacept</scp> Treated </scp> Pediatric Patients With <scp>Polyarticular</scp> Course </scp> Juvenile Idiopathic Arthritis: Findings From Two Phase <scp>III</scp> Clinical Trials. ACR Open Rheumatology, 2022, 4, 177-186.	0.9	3
696	Sodium – glucose cotransporter – 2 inhibitors and anemia among diabetes patients in real clinical practice. Journal of Diabetes Investigation, 2022, 13, 638-646.	1.1	7
697	Thrombectomy approach for access maintenance in the end stage renal disease population: a narrative review. Cardiovascular Diagnosis and Therapy, 2023, 13, 265-280.	0.7	5

#	ARTICLE	IF	CITATIONS
698	Evaluation of the Cost of a High-Dose Intravenous Iron Protocol in a Regional Hemodialysis Program: Research Letter. <i>Canadian Journal of Kidney Health and Disease</i> , 2021, 8, 205435812110639.	0.6	0
699	New-onset anemia and associated risk of ESKD and death in non-dialysis CKD patients: a multicohort observational study. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1120-1128.	1.4	10
700	Second-generation non-hematopoietic erythropoietin-derived peptide for neuroprotection. <i>Redox Biology</i> , 2022, 49, 102223.	3.9	4
701	Evaluation of recombinant human erythropoietin responsiveness by measuring erythrocyte creatine content in haemodialysis patients. <i>BMC Nephrology</i> , 2021, 22, 413.	0.8	4
702	Two Phase 3 Studies on Ophthalmologic Effects of Roxadustat Versus Darbepoetin. <i>Kidney International Reports</i> , 2022, 7, 763-775.	0.4	3
703	Association of anemia and iron parameters with mortality among prevalent peritoneal dialysis patients in Taiwan: the AIM-PD study. <i>Scientific Reports</i> , 2022, 12, 1269.	1.6	7
704	Role of Erythropoiesis-Stimulating Agents in Cardiovascular Protection in CKD Patients: Reappraisal of Their Impact and Mechanisms. <i>Cardiovascular Drugs and Therapy</i> , 2022, , 1.	1.3	2
705	Practical guidance for new multiple myeloma treatment regimens: A nursing perspective. <i>Seminars in Oncology</i> , 2022, , .	0.8	1
706	Extended Literature Review of the role of erythropoietin stimulating agents (ESA) use in the management of post renal transplant anaemia. <i>Transplantation Reports</i> , 2022, 7, 100097.	0.3	0
707	Kidney and heart failure outcomes associated with SGLT2 inhibitor use. <i>Nature Reviews Nephrology</i> , 2022, 18, 294-306.	4.1	64
708	An updated systematic review on heart failure treatments for patients with renal impairment: the tide is not turning. <i>Heart Failure Reviews</i> , 2022, 27, 1761-1777.	1.7	3
709	Pharmacotherapy to delay the progression of diabetic kidney disease in people with type 2 diabetes: past, present and future. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2022, 13, 204201882210816.	1.4	10
710	Effect of Roxadustat on the Pharmacokinetics of Simvastatin, Rosuvastatin, and Atorvastatin in Healthy Subjects: Results From 3 Phase 1, Openâ€Label, 1â€Sequence, Crossover Studies. <i>Clinical Pharmacology in Drug Development</i> , 2022, 11, 486-501.	0.8	3
711	Editorial: Erythropoietin and Its Analogues as Therapeutics for Neurological Diseases. <i>Frontiers in Pharmacology</i> , 2022, 13, 841538.	1.6	0
712	Effect of Phosphate Binders and a Dietary Iron Supplement on the Pharmacokinetics of a Single Dose of Vadadustat in Healthy Adults. <i>Clinical Pharmacology in Drug Development</i> , 2022, 11, 475-485.	0.8	2
713	Use of erythropoiesis-stimulating agents in children with chronic kidney disease: a systematic review. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1483-1505.	1.4	3
714	Optimizing detection of erythropoietin receptor agonists from dried blood spots for antiâ€doping application. <i>Drug Testing and Analysis</i> , 2022, 14, 1377-1386.	1.6	15
715	The clinical efficacy and safety of dapagliflozin in patients with diabetic nephropathy. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, 47.	1.2	4

#	ARTICLE	IF	CITATIONS
716	The Search for the Perfect Agent for Anemia Management in Chronic Kidney Disease. <i>Journal of the American Society of Nephrology</i> , 2022, 33, 662-664.	3.0	4
717	Treatment of anemia associated with chronic kidney disease with the <scp>HIF</scp> prolyl hydroxylase inhibitor enarodustat: A review of the evidence. <i>Therapeutic Apheresis and Dialysis</i> , 2022, 26, 679-693.	0.4	7
718	Development of spirulina for the manufacture and oral delivery of protein therapeutics. <i>Nature Biotechnology</i> , 2022, 40, 956-964.	9.4	50
719	Pharmacokinetics of Daprodustat and Metabolites in Individuals with Normal and Impaired Hepatic Function. <i>Clinical Pharmacology in Drug Development</i> , 2022, 11, 562-575.	0.8	4
720	Arrhythmias in Chronic Kidney Disease. <i>European Cardiology Review</i> , 2022, 17, e05.	0.7	7
721	The efficacy and safety of roxadustat for the treatment of anemia in non-dialysis dependent chronic kidney disease patients: An updated systematic review and meta-analysis of randomized clinical trials. <i>PLoS ONE</i> , 2022, 17, e0266243.	1.1	10
722	WT1: The Hinge Between Anemia Correction and Cancer Development in Chronic Kidney Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 876723.	1.8	0
723	Safety of daprodustat in patients with anemia of chronic kidney disease: A pooled analysis of phase 3 studies in Japan. <i>Therapeutic Apheresis and Dialysis</i> , 2022, , .	0.4	3
724	The ASCEND-ND trial: study design and participant characteristics. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2157-2170.	0.4	5
725	Trimming the fat: is there a health economic case for the use of new lipid-lowering drugs in chronic kidney disease? A scoping review. <i>CKJ: Clinical Kidney Journal</i> , 0, , .	1.4	0
726	Treatments for Chronic Kidney Disease: A Systematic Literature Review of Randomized Controlled Trials. <i>Advances in Therapy</i> , 2022, 39, 193-220.	1.3	12
727	Renal anemia and hydration status in non-dialysis chronic kidney disease: Is there a link?. <i>Journal of Medicine and Life</i> , 2018, 11, 293-298.	0.4	4
731	How Is Body Composition and Nutrition Status Associated with Erythropoietin Response in Hemodialyzed Patients? A Single-Center Prospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 2426.	1.0	5
732	Epidemiology and outcomes in patients with anemia of CKD not on dialysis from a large US healthcare system database: a retrospective observational study. <i>BMC Nephrology</i> , 2022, 23, 166.	0.8	6
733	Epoetin alfa in Pediatric Patients With Ventricular Assist Devices: Is It Safe?. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2022, 27, 384-389.	0.3	0
735	Efficacy of Different Doses of Daprodustat for Anemic Non-dialysis Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 2722.	1.0	2
736	Efficacy of daprodustat on anemia in hemodialysis patients with sustained inflammation: a case report. <i>CEN Case Reports</i> , 2022, , .	0.5	0
737	Revisiting anemia in sickle cell disease and finding the balance with therapeutic approaches. <i>Blood</i> , 2022, 139, 3030-3039.	0.6	8

#	ARTICLE	IF	CITATIONS
738	An analysis of vascular access thrombosis events from the Proactive IV Iron Therapy in Hemodialysis Patients (PIVOTAL) trial. <i>Kidney International Reports</i> , 2022, , .	0.4	1
739	Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience. <i>BioDrugs</i> , 2022, 36, 359-371.	2.2	14
740	Longitudinal Evaluation of Cytopenias in the Renal Transplant Population. <i>Transplantation Direct</i> , 2022, 8, e1339.	0.8	1
741	Repurposing drugs for highly prevalent diseases: pentoxifylline, an old drug and a new opportunity for diabetic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 2200-2213.	1.4	3
742	Tetrahydropyridin-4-ylpicolinoylglycines as novel and orally active prolyl hydroxylase 2 (PHD2) inhibitors for the treatment of renal anemia. <i>European Journal of Medicinal Chemistry</i> , 2022, 238, 114479.	2.6	3
743	<sc>Erythropoiesisâ€stimulating</sc> Agents and Incident Malignancy in Chronic Kidney and <sc>Endâ€Stage</sc> Renal Disease: A <sc>Populationâ€Based</sc> Study. <i>Clinical and Translational Science</i> , 0, , .	1.5	1
744	Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018. <i>Advances in Therapy</i> , 2022, 39, 3711-3734.	1.3	4
745	A 46-Year-Old Thai Woman with Secondary Acquired Pure Red Cell Aplasia Due to Treatment with Recombinant Erythropoietin While on Dialysis for End-Stage Renal Disease Who Recovered Following ABO-Incompatible Kidney Transplantation. <i>American Journal of Case Reports</i> , 0, 23, .	0.3	3
746	Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease. <i>American Journal of Hematology</i> , 0, , .	2.0	6
747	Administration of Î±-Klotho Does Not Rescue Renal Anemia in Mice. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	2
748	Interchangeability for Biologics is a Legal Distinction in the USA, Not a Clinical One. <i>BioDrugs</i> , 2022, 36, 431-436.	2.2	4
749	Relevance of pre-existing anaemia for patients admitted for acute coronary syndrome to an intensive care unit: a retrospective cohort analysis of 7418 patients. <i>European Heart Journal Open</i> , 2022, 2, .	0.9	1
750	Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study. <i>Psoriasis: Targets and Therapy</i> , 0, Volume 12, 199-204.	1.2	7
751	Predictors of iron versus erythropoietin responsiveness in anemic hemodialysis patients. <i>Hemodialysis International</i> , 0, , .	0.4	1
752	Renin-angiotensin system blockers-SGLT2 inhibitors-mineralocorticoid receptor antagonists in diabetic kidney disease: A tale of the past two decades!. <i>World Journal of Diabetes</i> , 2022, 13, 471-481.	1.3	3
753	High yield secretion of human erythropoietin from tobacco cells for ex vivo differentiation of hematopoietic stem cells towards red blood cells. <i>Journal of Biotechnology</i> , 2022, 355, 10-20.	1.9	1
754	Gut Microbiota Correlates With Clinical Responsiveness to Erythropoietin in Hemodialysis Patients With Anemia. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	2
755	Physical Activity and Exercise for Cardiorespiratory Health and Fitness in Chronic Kidney Disease. <i>Reviews in Cardiovascular Medicine</i> , 2022, 23, 273.	0.5	3

#	ARTICLE	IF	CITATIONS
756	Microglial polarization in TBI: Signaling pathways and influencing pharmaceuticals. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	11
757	Protein Design: From the Aspect of Water Solubility and Stability. <i>Chemical Reviews</i> , 2022, 122, 14085-14179.	23.0	54
758	Heart failure-type symptom scores in chronic kidney disease: The importance of body mass index. <i>International Journal of Obesity</i> , 2022, 46, 1910-1917.	1.6	1
759	Bioinspired Design of Artificial Signaling Systems. <i>Biochemistry</i> , 2023, 62, 178-186.	1.2	0
760	Hemodialysis facility star rating affects mortality in chronic hemodialysis patients: a longitudinal observational cohort study. <i>Kidney Research and Clinical Practice</i> , 2023, 42, 109-116.	0.9	4
761	Detection of innate immune response modulating impurities (IIRMI) in therapeutic peptides and proteins: Impact of excipients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
762	Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2022, 18, 696-707.	4.1	101
763	Evaluating group-sequential non-inferiority clinical trials following interim stopping: The HIV Prevention Trials Network 083 trial. <i>Clinical Trials</i> , 0, , 174077452211183.	0.7	0
764	Bibliometric analysis of hypoxia inducible factor prolyl hydroxylase inhibitor in anemia. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
765	Identification and single-base gene-editing functional validation of a cis-EPO variant as a genetic predictor for EPO-increasing therapies. <i>American Journal of Human Genetics</i> , 2022, 109, 1638-1652.	2.6	5
766	FREQUENCY OF IRON DEFICIENCY ANEMIA IN NON-DIALYSIS CHRONIC KIDNEY PATIENTS. <i>Pakistan Journal of Kidney Diseases</i> , 2022, 6, 17-22.	0.0	0
767	Anemia Prevalence, Type, and Associated Risks in a Cohort of 5.0 Million Insured Patients in the United States by Level of Kidney Function. <i>American Journal of Kidney Diseases</i> , 2023, 81, 201-209.e1.	2.1	13
768	Anemia in CKD in Primary Care: Executive Summary. <i>Clinical Diabetes</i> , 0, , .	1.2	0
769	Association of anaemia with long-term mortality among patients with hypertensive crisis in the emergency department. <i>Annals of Medicine</i> , 2022, 54, 2740-2747.	1.5	1
770	Oncology biosimilars: New developments and future directions. <i>Cancer Reports</i> , 2022, 5, .	0.6	6
771	Association between haemoglobin concentration and intradialytic hypotension in patients undergoing maintenance haemodialysis: a retrospective cohort study. <i>BMJ Open</i> , 2022, 12, e064026.	0.8	0
772	The Influence of Iron-Deficiency Anaemia (IDA) Therapy on Clinical Outcomes and Healthcare Resource Consumptions in Chronic Kidney Disease Patients Affected by IDA: A Real-World Evidence Study among the Italian Population. <i>Journal of Clinical Medicine</i> , 2022, 11, 5820.	1.0	1
773	Effects of Zinc Acetate Hydrate Supplementation on Renal Anemia with Hypozincemia in Hemodialysis Patients. <i>Toxins</i> , 2022, 14, 746.	1.5	4

#	ARTICLE	IF	CITATIONS
774	A Novel Bootstrapping Test for Analytical Biosimilarity. <i>AAPS Journal</i> , 2022, 24, .	2.2	0
775	Synergistic deterioration of prognosis associated with decreased grip strength and hyporesponse to erythropoiesis-stimulating agents in patients undergoing hemodialysis. <i>Renal Failure</i> , 2022, 44, 1811-1820.	0.8	2
776	Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia. <i>Kidney Diseases (Basel, Switzerland)</i> , 2023, 9, 1-11.	1.2	7
778	Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis. <i>Circulation</i> , 2022, 146, 1383-1405.	1.6	118
779	Management of anaemia in French dialysis patients: results from a large epidemiological retrospective study. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 501-511.	1.4	2
780	Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors. <i>Drugs</i> , 2022, 82, 1565-1589.	4.9	17
781	Investigating Severe Adverse Reactions: Examples of the ANTICIPATE Methodology at Work. <i>Cancer Treatment and Research</i> , 2022, , 129-140.	0.2	0
782	Comparison of efficacy of roxadustat and erythropoietin for the treatment of renal anemia in patients with chronic kidney disease: a retrospective study. <i>Translational Andrology and Urology</i> , 2022, 11, 1568-1576.	0.6	3
783	Preferences for Anaemia Treatment Attributes among Patients with Non-Dialysis-Dependent Chronic Kidney Disease. <i>Advances in Therapy</i> , 2023, 40, 641-657.	1.3	4
784	Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials. <i>American Journal of Nephrology</i> , 2022, 53, 701-710.	1.4	2
785	Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: The BRIGHTEN study. <i>PLoS ONE</i> , 2022, 17, e0277921.	1.1	2
786	An Institutional Guide for Formulary Decisions of Biosimilars. <i>Hospital Pharmacy</i> , 2023, 58, 38-48.	0.4	4
787	Identification of the Genetic Association Between Type-2-Diabetes and Pancreatic Cancer. <i>Biochemical Genetics</i> , 2023, 61, 1143-1162.	0.8	0
788	Biosimilars in Oncology: Latest Trends and Regulatory Status. <i>Pharmaceutics</i> , 2022, 14, 2721.	2.0	6
789	A Retrospective Study of the Perioperative Period Management of Joint Arthroplasty in Patients with Chronic Kidney Disease. <i>Orthopaedic Surgery</i> , 0, , .	0.7	0
790	Impact of N-Linked Glycosylation on Therapeutic Proteins. <i>Molecules</i> , 2022, 27, 8859.	1.7	9
791	Hemoglobin and Clinical Outcomes in Hemodialysis: An Analysis of US Medicare Data From 2018 to 2020. <i>Kidney Medicine</i> , 2023, 5, 100578.	1.0	2
792	The role of roxadustat in chronic kidney disease patients complicated with anemia. <i>Korean Journal of Internal Medicine</i> , 2023, 38, 147-156.	0.7	2

#	ARTICLE	IF	CITATIONS
793	Beneficial effect of roxadustat on early posttransplant anemia and iron utilization in kidney transplant recipients: a retrospective comparative cohort study. <i>Annals of Translational Medicine</i> , 2022, 10, 1360-1360.	0.7	1
794	The impacts of hypoxia-inducible factor stabilizers on laboratory parameters and clinical outcomes in chronic kidney disease patients with renal anemia: a systematic review and meta-analysis. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 845-858.	1.4	9
795	Is serum hemoglobin level an independent prognostic factor for IgA nephropathy?: a systematic review and meta-analysis of observational cohort studies. <i>Renal Failure</i> , 2023, 45, .	0.8	1
796	Chronic Kidney Disease as a Comorbidity in Heart Failure. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2988.	1.8	9
797	Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies. <i>Advances in Therapy</i> , 2023, 40, 1546-1559.	1.3	3
798	Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	4
799	Assessment of the differences between generic and biosimilar drugs: A brief literature review. <i>Journal of Generic Medicines</i> , 0, , 174113432311573.	0.0	2
800	Clinical features of anemia in membranous nephropathy patients: a Chinese cohort study. <i>Renal Failure</i> , 2023, 45, .	0.8	0
801	Cardiorenal syndrome in the pediatric population: A systematic review. <i>Annals of Pediatric Cardiology</i> , 2022, 15, 493.	0.2	0
802	Hypoxia-inducible factor stabilizers: 27 228 patients studied, yet a role still undefined. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 776-779.	1.4	1
803	Patient Blood Management, Anemia, and Transfusion Optimization Across Surgical Specialties. <i>Anesthesiology Clinics</i> , 2023, 41, 161-174.	0.6	0
804	Three-year safety observation of subcutaneous administration of epoetin-zeta in patients with chronic renal anemia: Results from PASCO II study. <i>Clinical Nephrology</i> , 2023, , .	0.4	0
805	The Association between Iron Deficiency and Renal Outcomes Is Modified by Sex and Anemia in Patients with Chronic Kidney Disease Stage 1-4. <i>Journal of Personalized Medicine</i> , 2023, 13, 521.	1.1	0
806	Impact of anemia treatment for left ventricular hypertrophy using long-acting erythropoietin-stimulating agents from the pre-dialysis to maintenance dialysis period in patients with chronic kidney disease, retrospective longitudinal cohort study. <i>BMC Nephrology</i> , 2023, 24, .	0.8	0
807	Comparative Study of Recombinant Human Erythropoietin (rhEPO) Products on CKD (Chronic Kidney) Tj ETQq0 0 0,rgBT /Overlock 10 T	0.7	0
808	Predictors of quality of life in patients within the first year of commencing haemodialysis based on baseline data from the PIVOTAL trial and associations with the study outcomes. <i>Journal of Nephrology</i> , 2023, 36, 1651-1662.	0.9	1
809	Blood doping-physiological background, substances and techniques used, current and future detection methods. <i>Science and Sports</i> , 2023, , .	0.2	0
810	Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors versus erythropoiesis-stimulating agents on iron metabolism and inflammation in patients undergoing dialysis: A systematic review and meta-analysis. <i>Heliyon</i> , 2023, 9, e15310.	1.4	2

#	ARTICLE	IF	CITATIONS
811	Current applications of biomolecules in biopharmaceuticals and drug discovery. , 2023, , 439-466.		0